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Chapter 1 - General Introduction
History of blood data
If the practice of bloodletting is taken into account, blood products or manipulation 
thereof can easily be considered the oldest healthcare application, be it not very healthy 
at the beginning. For example, historic records regularly mention the drawing of blood 
from critically ill, or transfusing animal blood into humans. At best this renders recipients 
of this type of treatment anemic, but more adverse effects like sepsis alloimmune 
reaction would mean certain death in those days. 
Red blood cells, RBCs, make up the majority of our blood cells and some reports even 
suggest over 75% of the cells in our body cell.1 Their main function is oxygen transport. 
Consequently, too few RBCs in circulation can result in insufficient oxygenation of 
tissues, a condition that is referred to as anemia. Anemias range from mild to lethal 
depending on source of RBC breakdown.
In order to be able to transport oxygen RBCs are packed with hemoglobin molecules. 
Hemoglobin is a tetrameric molecule that consists of two identical subdomains, the 
globin chains, that change throughout development in a process called hemoglobin 
switching. Perhaps unsurprisingly given the early fascination for blood in health and 
disease, the high abundance of blood cells in our bodies and hemoglobin as main 
molecule within these cells, the field of hemoglobin switching competes for the crown 
in the category oldest field in human molecular biology. 
Figure 1. Schematic depiction of showing share of hemoglobin types at different stages of development.
The central premise for the hemoglobin switching field is shown in figure 1, the 
illustration is adapted from a figure that first appeared in Annals of New York Academy 
of sciences in 1974.2 It shows how hemoglobin composition changes throughout human 
development in the two hemoglobin switches: an embryonic-to-fetal and a fetal-to-adult 
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switch. These switches occur as the main sites for erythropoiesis migrate from the yolk-
sac to the fetal liver and later the bone marrow and are characterized by expression of 
the different globin genes. In the end this translates to most adults expressing less than 
0.5% of fetal hemoglobin, HbF. Deviations from this normalcy have been of great interest 
since the early days of the hemoglobin switching field. 
While the graph from figure 1 is commonly used to summarize the history of the 
entire field, it omits how research on hemoglobin switching serves as a great example 
of knowledge development co-evolving with technological innovation. This chapter 
summarizes how such combined developments have shaped the hemoglobin switching 
field in search of therapeutic approaches for hemoglobinopathies. 
The first part of this introduction will set the stage by discussing the key discoveries 
that brought the hemoglobin switching field to the start of this millennium. A complete 
overview of the period is beyond the scope of this introduction. Instead it will focus on 
the core concepts that are important for the research on the fetal-to-adult switch in this 
thesis. It will take cues from several reviews that have provided more detailed accounts 
of the entire period at different time intervals.3–6
The two most recent decades of hemoglobin switching research will be addressed in 
the second part of the introduction. There I will employ natural language processing 
techniques to provide an overview of the literature on the hemoglobin switch. In 
addition to introducing the most recent progress in the field, this approach provides an 
example of how new means of data analysis are a central part of today’s technological 
advances. 
Blood and biology: seeing what life is made off
Starting my PhD research across the street from the Antoni van Leeuwenhoek hospital 
in a Landsteiner Laboratory I’ll set off the introduction with the work of these two 
historical scientists. The Dutch lens maker Antoni van Leeuwenhoek paved the way to 
our knowledge on red blood cells, RBCs. Using his microscope, he was able to describe 
these ‘red bodies’ for the first time in 1695.7 At that time, knowledge on the role of blood 
in health and disease was rudimentary at best, and only started to rise with the discovery 
of blood groups. At the start of the twentieth century Karl Landsteiner showed that 
blood serum from different individuals would only clump the red blood cells from 
certain other individuals. Initially, he reported on three different groups, a fourth group 
was reported shortly thereafter8 The ABO-blood group system was born and provided 
the basis for the first curative blood transfusions. The method which today is still a 
mainstream treatment for sickle cell disease (SCD) and thalassemia patients. 
12
Chapter 1 - General Introduction
The thalassemia text book, from the early ‘80s now in its fourth edition, is an excellent 
resource on the earliest history of hemoglobin research. It notes that several early 
reviews have placed records on a hemoglobin-associated phenomenon even before the 
discovery of the RBCs. For instance, in 1566 Michael Servetus described how blood 
changes color in the lung, which we now know results from the cells taking up oxygen.9 
Although the earliest account of different hemoglobin types stems from the 19th 
century, validation of the differences between adult and newborn hemoglobin followed 
in the the early 20th century;  the combination of alkaline sensitivity, - and electrophoretic 
separation assays led to the identification of two distinct types of hemoglobin.10 
Along with the discoveries in blood this era hosted fundamental discoveries with 
respect to the way we understand life today; the (re)discovery of Mendel’s work on 
hereditary traits, the discovery of the nuclear bases by Albrecht Kossel (both originating 
around the start of the century), the 46 chromosomes by de Winiwarter and Painter 
(1912 and 1923 respectively), although mistakenly quantified at 47 then 48 until the 
1950 and the hereditary units on the chromosome, now genes, by Thomas Hunt Morgan 
in 1913.11–14
In the 300 years since the first record of cells within our blood, natural science had 
discovered the basic building blocks of the inside of cells. Still there was a long road 
ahead towards understanding how these parts would fit together with the different 
hemoglobin phenotypes. 
Aberrant globin expression: nature’s laboratory
Where the earliest discoveries on blood resulted from anatomical observation, much 
of the early knowledge on hemoglobin stems from population studies, describing the 
phenomena from nature’s own laboratory. With the advent of x-ray crystallography, 
hemoglobin followed the example of whale myoglobin to become the first human protein 
for which the structure was identified.15,16 This early work found that adult hemoglobin 
consists of two α and two β chains, fetal hemoglobin has α chains linked with two γ 
chains and embryonic hemoglobin pairs two ζ chains with two ε chains, or intermediate 
forms consisting of alpha epsilon pairing. Although the chains are similar when it comes 
to the subdomains, the specific amino acid sequences result in different electrophoretic 
properties of each chain. 
Hemoglobin variants
The properties of the different globin chains were exploited with the advent of 
electrophoretic shift assays using paper as the carrier. Taking this assay to test 
the human population revealed how variants of the normal hemoglobin molecule 
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are at the basis of different anemic phenotypes. The molecular origin of sickle 
cell disease, SCD, was first described by Linus Pauling.17 Thalassemia and other 
causes of anemia followed this description shortly after that and brought an 
increasing interest in describing the exact molecular composition of hemoglobin 
molecules.18 Today’s sequencing-based screening approaches have revealed the 
presence of different hemoglobin molecules in health as well, now over 1300 
variants that result from single nucleotide polymorphisms, SNPs, to one of the globin 
chains are listed on the Globin server.19,20 Combined with the thalassemia mutations this 
bring the total number of different hemoglobin molecules at 1815. Disease phenotypes 
that result from these variants are aptly called hemoglobinopathies. 
β-hemoglobinopathies
Hemoglobinopathies include the most frequently occurring hereditary anemias 
and monogenic diseases; Sickle cell disease (SCD) and β-thalassemia.21 These 
β-hemoglobinopathies result from a range of mutations in or associated with the HBB 
gene encoding β-globin. 
β-thalassemia results from mutations or deletions in either the β-globin gene itself, or 
in the regulatory regions of the gene. Research on the latter group led to the discovery of 
many of the regulatory elements of the globin genes, which are a topic of a later section 
of the introduction. The severity of the disease ranks from minor to major depending 
on the type of the mutation.22 Regardless of the severity of β-thalassemia, globin-
chain imbalance, i.e. non-matching globin chain levels causing misfolded hemoglobin 
molecules, is one of the main causes for early decay of red blood cells and the resultant 
anemia in this type of disease. 
SCD results from a single base-pair substitution that causes the glutamic acid residue 
at position 6 to be substituted by a valine residue (p.E6V).23 The resultant hemoglobin 
molecules polymerize in low-oxygen environments, which leads to loss of deformability 
of the cells. This gives cells their characteristic sickled shape, can cause vaso-occlusive 
events. Repeated cycles of sickling in hypoxic and unsickling in normoxic conditions 
leads to a loss in membrane deformability and increased breakdown of red cells in the 
spleen. 24,25 
Hereditary persistence of fetal hemoglobin
Along with the characterization of alternate globin molecules it became possible to 
investigate why certain anemic traits did not follow Mendelian inheritance patterns. This 
led to the discovery of fetal hemoglobin expression in adults.26,27 This observation was 
extended to healthy populations, when the screening of Swiss-army recruits revealed 
that around 0.01% of that population had fetal hemoglobin at levels over 0.7% of total 
hemoglobin.28 The phenotype became known by the general term hereditary persistence 
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of fetal hemoglobin (HPFH), referring to adult individuals with HbF levels exceeding 
0.5% of total hemoglobin.
Since the initial report, different forms of HPFH associated with the adult-globin 
locus have been described. These fall in two main categories; deletional and non-
deletional HPFH. In the deletional form HPFH results from large deletions in the HBB 
locus, resulting in large stretches or even complete loss of the adult globin genes (see 
figure 2 for schematic representation of the locus). The non-deletional forms displays 
HPFH as a result of single base pair polymorphisms or small (<15bp) deletions, that 
occur in sites that are critical for regulation of globin expression, like for example the 
binding site for BCL11A at position -114 in promoter of γ-globin, that will be discussed 
in a later section of the introduction. A recent review summarized at least 9 forms of 
deletional- and 16 non-deletional HPFH.29 In addition to mutations associated with the 
HBB locus itself, mutations in some of the hemoglobin regulators are associated with 
HPFH as well. 
The variety of mutations that cause HPFH result in a remarkable variance of the 
resultant HbF levels, these range between 1% to 41% for specific cases with a single 
mutation in one allele. In contrast, β-thalassemia mutations that also induce HbF always 
results from two affected two alleles. In this the case certain deletional forms to express 
up to 90% HbF, due to a complete lack of a functional HBB gene.30,31
In the event of combined HPFH and β-hemoglobinopathies, disease severity was found 
to be inversely correlated with HbF expression and levels above 20% of total hemoglobin 
have been suggested to relieve patients of the need for recurrent transfusions.32,33
Chemical induction of fetal hemoglobin experession
The amelioration of disease symptoms with higher HbF levels, made the mechanism 
behind HbF variation and means of inducing HbF levels an important topic for 
investigation. Early success with the chemical induction of HbF came from tests with DNA-
demethylating agents, 5-azacytidine and decitabine, and an inhibitor of ribonucleotide 
synthesis, hydroxyurea (HU). Latter was initially used as a cytotoxic drug control 
condition.34,35 Later clinical trials showed that the drug induces HbF with tolerable side 
effects compared to a native course of the disease, making it the only drug for treating 
sickle cell patients that is approved by the federal drug association and still the main 
treatment for SCD patients today.36–38
Other chemical inducers of HbF showed promise on initial tests, but failed to make it 
beyond the stage of clinical trials. Either due to lack of efficacy, or due to cytotoxic side 
effects. These include dimethylbutyrate that act as histone deacetylase inhibitors, and DNA 
demethylating agents like 5-azacytidine.39–42 While most alternative treatment options 
did not make it in to the clinic, they did suggest a role for the targeted mechanisms, like 
DNA methylation and Histone deacetylation, in the regulation of the hemoglobin switch. 
15
1
Yet the lack of specificity for these agent makes their true relevance for the regulation of 
the globin genes questionable. 
What started from describing the phenotype in populations, progressed with 
describing the proteins behind the phenotypes and turned into attempts at treating 
hemoglobinopathies. 
With this the studies in nature’s lab brought the field from the inside of patient to the 
interior of the cells. In the process these studies contributed to the discovery of most 
components of the hemoglobin switch, ranging from the genes themselves, epigenetics, 
regulatory elements and transcription factors that control gene expression. The following 
paragraphs will discuss these components as it extends the focus to the inside of the 
nucleus, were DNA holds the hereditary information that allows phenotypes to spread 
throughout populations.
Hemoglobin as a model for gene expression
While the chromosomes were already known since the start of the 20th century, electron 
microscopy of these structures found that they consisted of DNA fibers wrapped around 
nucleosomes. Winding 146 base pairs of DNA around each nucleosome allows the fibers 
to compact into chromatin and fit all the hereditary information inside the nucleus.43 
The discovery of the double helix structure of DNA itself provided the basis for unifying 
the chromosomes, nucleic acids, genes and hereditary traits in a single model. Initially, 
how the DNA would hold hereditary information and how this would “Translate” in to 
the production of proteins remained a mystery. These questions were addressed by 
the rise of molecular biology that followed in the decades after the discovery of the 
double helix marked the next important step in acquiring knowledge on hemoglobin 
switching. 
As an interesting side note, the interdisciplinary efforts that led to these discoveries 
started from viewing hereditary traits in terms of code and information transfer, which 
crossed over from the fields of physics and mathematics in the 1940s, a period in which 
the term “molecular biology” was coined for the first time.44 
Prior to the advent of molecular biology, the work on anemias had focused on 
the proteins at the basis of phenotypes. The discovery of DNA and its hypothesized 
role in storing hereditary information shifted the focus towards identifying how the 
information to make proteins is stored and how it is processed in cells to ultimately 
affect phenotypes.
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From proteins to genes
Molecular cloning techniques facilitated the search for genes associated with the 
proteins that make up different hemoglobin molecules. Aside from efforts to find the 
regions on the DNA, the messenger RNA was described to carry genetic information 
out of the nucleus to be translated in to proteins in the cytosol.45 Introduction of this 
intermediate step paved the way for questions on the regulation of gene expression that 
came to govern molecular biology as more genes along with their location and their 
regulatory elements were discovered. 
The charting efforts of the DNA identified chromosome 11 as the region that harbors 
the genes at the basis for different globin chains involved in the fetal-to-adult switch; 
the HBB locus. Along the HBB locus genes line up from the embryonic epsilon- (HBE), to 
the two fetal gamma- (HBG2 and HBG1), and ultimately the delta- (HBD) and beta-globin 
(HBB) gene (see review by Maniatis et al.46). Upstream of the locus there is a region that 
was termed locus control region. It consists of five DNase I hypersensitive sites, regions 
of accessible chromatin that are of pivotal importance for gene expression from the 
locus.47–49 
Figure 2. Schematic layout of the HBB locus. Top illustration shows the orientation of the genes on the 
adult globin locus, along with the upstream locus control region consisting of 5 DNAse I hypersensitive 
sites (DHS). The DHS downstream of the locus is not depicted here (for more detailed mapping of 
the locus see F3 of chapter 4). Bottom part shows an illustration of DNA strands wrapping around 
nucleosomes (147basepair per turn) to further compression of genetic material into chromosomes.
17
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From DNA to protein
The developmental expression pattern of the globin genes along with the complete 
sequence map made the globin locus an invaluable model system for studies on 
regulation of gene expression. The smallest unit of genetic regulation of gene expression 
is the base pair sequence, where specific sequences make up regulatory elements that 
provide docking sites for the proteins that initiate transcription or have a different role 
in regulation. 
Directly upstream of the 5’ start of the transcription start site for a gene the TATA-
box and initiator-sequence, together with downstream promoter elements, provide 
docking for the transcription preinitiation complex (PIC) and RNA polymerase II (PolII), 
the protein that can synthesize RNA during transcription. Further upstream in cis (on the 
same DNA molecule) sequences like the CCAAT-, CG-box and other enhancer elements 
can recruit co-activators like CCAAT-binding protein (C/EBP), activating protein 1 (AP-1). 
Further in cis sequences that make up binding-sites for nuclear factors (NF) and hormone 
responsive elements (HRE) have also been shown to contribute to the formation of the 
transcriptional complexes (reviewed by Lemon and Tjian50). Both the TATA- and CCAAT-box 
are shared by the proximal promoter sequences of many of the globin genes (reviewed in 
Philipsen and Hardison51). The proteins that bind these general sequences interact with 
those binding at sequences that are specific for lineage restricted transcription factors to 
result in tissue specific transcription of mRNA. 
Lineage-specific regulation
Control of gene expression at sequence level extends in to lineage specific regulation. 
For example, the CACCC-elements, found at -80 base pairs of the transcription initiation 
site in globin promoters, are recognized by the erythroid specific transcription factor 
Krupple like factor 1 (KLF1). Along with GATA1 and NF-E2 this was described as the 
earliest (master)regulators of erythropoiesis.52–55 Combinatorial interactions between 
the lineage specific transcription factors along with those that bind general regulatory 
sequences form an additional layer of transcription factor networks that control gene 
expression. Next to erythroid specific factors, the core transcription factors that regulate 
hemoglobin switching include BCL11A and LRF, which will be discussed in more detail 
in the second part of the introduction.56,57 
Epigenetic regulation
In addition to regulatory sequences and transcription factor combinatorics, epigenetic 
modifications to the DNA form another layer that controls gene expression. To this end 
complexes of general and lineage specific factors can include proteins that place these 
modifications on the DNA or chromatin structure, for example methylation of cytidine 
residues, or placing various chemical side groups on the tails of histones that make 
18
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up the nucleosomes. In turn these results in altered chromatin accessibility and gene 
expression. 
In the context of hemoglobin switching DNA methylation of CpG residues was the 
earliest epigenetic mechanism implicated in developmental gene regulation, while 
acetylation of histones tails potentially controls globin expression by affecting the 
accessibility of the DNA in the 30nm chromatin fiber.58–60 In the previous section on 
chemical induction of HbF, we discussed how the use of DNA demethylating agents such 
as 5-azacytidine, and histone deacetylation inhibitors such as butyrate and trichostatin 
A suggests the importance of these epigenetic layers in regulation of the globin gene 
expression.61–63 On the other hand, the lack of broadscale efficacy in altering globin 
gene expression with these agents in clinical setting raises the question to what 
extend epigenetics directly drives activation or inhibition of globin gene expression. 
Distal regulation
The regulation mechanisms described up to this point focus on the on-site drivers 
and inhibitors of gene expression. DNA sequences in the promoter bind both general 
and specific transcription factor, that in complex with epigenetic modifiers affect 
local chromatin structures and gene expression. 
However, beyond these local interactions, DNA sequences located further away 
from the transcription start sites also contribute to transcriptional regulation. 
Initially, such transcriptional enhancer sequences were reported within 1kb from 
transcription start sites, for example the SV40 enhancer that was found to increase 
gene expression of their associated genes. 64 Later, the β-globin locus was the first 
genomic region for which a long-range DNA interaction were reported to affect gene 
expression. The discovery of the HBB locus control region (LCR) showed that enhancer 
sequences can act from as far as 60kb in the case of the HBB gene.47–49 
The potential for long-range interactions makes the 3D-organisation of the DNA-
chromatin fiber a fourth layer of regulation at the level of the genome. Ultimately, 
chromatin loops were discovered to place the enhancer element from the LCR in 
trans of the beta-globin promoter to positively influence gene expression.65 This will 
be discussed in a section on the more recent advances in the hemoglobin switching 
field. 
Additional layers of regulation such as non-coding-, small RNAs at genome level 
and post-translational modifications and alternative isoforms of transcription factors 
at protein level also feed into the mix of transcriptional regulation.66–70 Since there 
is limited evidence for this type of regulation affecting the globin genes, these 
additional modes of regulation are beyond the scope of this introduction. 
Following the early mapping of the locus and the identification of different 
regulatory layers, hemoglobin switching emerged as a convenient model to study 
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regulation of gene expression throughout erythroid development. The following 
paragraphs discuss the process by which red blood cells are formed.
Erythropoiesis throughout development: Regulation 
and the environment
From a historical perspective developmental erythropoiesis is intertwined with all of 
the proceedings described in the previous paragraphs. From the first observations on 
different hemoglobin types in adult and neonatal blood, through DNA modifications at 
specific developmental stages, to the formation of transcription factor complexes, each 
of these developments aimed to understand how the hemoglobin genes are expressed 
as RBCs develop from hematopoietic stem-and progenitor cells. 
Hematopoiesis
The description of cells in our blood other than RBCs dates back to mid-19th century, 
the same period as the first description of hemoglobin within red cells.71 Contrasting 
to RBCs these other cells did not appear to have a color and were called leukocytes 
(leuko after white in Greek). At the beginning of the 20th century, early hypotheses by 
Neuman and Maximov proposed that a single cell type, residing in the bone marrow, 
could be the source for red and white blood cells (see review by Boisset and Robin72).
In comparison to red blood cells the research on hematopoietic stem- and 
progenitor cells was held back by problems of scale and accessibility. Not until the 
first bone marrow transplantation had been performed, did the experimental evidence 
in mouse models demonstrate the ability of donor bone marrow to reconstitute all 
blood lineages in a recipient.73,74 
Hematopoiesis is classically depicted in a tree like structure; one hematopoietic 
stem progenitor cell (HPSC) differentiates in to more specialized branches of 
progenitors to give rise to five specific blood cell types as the leaves of the tree.75,76 
With recent advances in single cell sequencing approaches the classical tree-model 
has been challenged by a model that favors gradually shifting gene expression and 
cellular identity. With it a discussion has started on the origin of cell fates, the extent 
to which genetic information controls the future cell type(reviewed by Laurenti and 
Göttgens77). 
Erythropoiesis
Erythropoiesis concerns the erythroid specification from progenitor cells. 
Throughout ontogeny, the process is thought to occur in different developmental 
waves.78 Although the general concept of cell fate changes, a multipotent cell 
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that is increasingly restricted in its potential, is similar across all developmental 
processes, two distinct erythroid waves can be distinguished. Primitive and definitive 
erythropoietic waves differ in key characteristics, like their progenitor cell, cellular 
environment, morphology and hemoglobin expression (Figure 3).79,80 
Hemangioblast-derived hematopoietic progenitors give rise to erythroid cells in the 
yolk sac during the primitive wave, while the HSC, that arises from the aorto-gonadal-
mesonephros region at embryonic day E9-E10, does so in the fetal liver and the bone 
marrow during the definitive wave. Primitive erythroid cells are larger compared to 
definitive cells and mature in the circulation, where they eventually lose their nucleus. 
In contrast, definitive cells only enter the circulation after enucleation has occurred.80 
Figure 3. Key characteristics of developmental erythroid waves. 
Enucleation
Enucleation is the final step in erythropoiesis and can be considered an extreme cell 
fate decision. The cell expels the blueprint of life, rendering it unable to divide and 
abrogating long-term survival. 
Although the latest progenitor to maintain extensive dividing capacities is the pro-
erythroblast (pro-EBL), the magnitude of this potential is unclear in vivo. Microscopic 
dissection of the bone marrow described various stages of cells that make up the 
transition towards the enucleated cell; terminal differentiation 81. In this process pro-
EBL undergo a limited number of cells divisions (basophilic erythroblast), gradually 
decrease in size, while they accumulate hemoglobin (polychromatic), condense the 
nucleus (orthochromatic normoblast), breakdown or expel most of their organelles and 





The extreme fate decision that occurs in erythropoiesis is thought to be controlled 
by balancing signals from the cellular environment. On one hand, these signals 
consist of (soluble) growth factors, such as stem cell factor (SCF), erythropoietin (EPO), 
Vascular endothelial growth factor (VEGF) and insulin like growth factor that stimulate 
erythropoiesis and inflammatory signals such as tumor necrosis factor, interferon gamma 
and tissue growth factor beta (TNF, IFNγ and TGFβ respectively) that negatively regulate 
erythropoiesis ( see review by Tsiftsoglou et al., 2009). On the other hand, these signals 
originate from cell-cell interactions within a specific erythroid niche, more on that in 
the next section. Of the stimulatory growth factors, the role of EPO and SCF is best 
understood, in part because these are essential factors for in vitro erythropoiesis. 
SCF can be produced by various cell types, in both soluble and membrane-bound forms 
and binds to the KIT receptor. 85–87 While the soluble form is sufficient to sustain in vitro 
erythropoiesis, mice that lack the transmembrane form are anemic.88,89 Although SCF 
has a general role of accelerating cell cycle entry in hematopoiesis, in combination with 
other growth factors such as IL3 it greatly enhances the expansion capacity of erythroid 
progenitors and is suggested to positively influence long-term HSPC maintenance in-
vivo as well. 90–93 In erythropoiesis the interaction of the KIT and EPO receptor (EpoR) 
signaling is critical for erythroid progenitor development and retards the differentiation 
of these progenitors, adding to their expansion potential and stimulating the production 
of fetal hemoglobin in adult erythroid cultures.94–96 
Well before any record of a role for SCF in hematopoiesis, EPO was recognized as the 
body’s main erythroid hormone. It is produced by the kidneys and provides the main 
stimulus for production of erythroid cells in the bone marrow.97 In response to low 
oxygen tension in the environment or as a result of anemia EPO production increases 
to boost RBC production. This results in the process of stress erythropoiesis which will 
be discussed further on. 
Aside from the synergy with SCF/KIT signaling that supports development of early 
erythroid progenitors, EpoR signaling promotes erythropoiesis through activation of 
PI3K, MAPK and JAK2 and STAT5 signaling. These pathways induce expression of Bcl-XL, 
an anti-apoptotic protein.98–101
SCF-induced PI3 kinase signaling prevents terminal differentiation of erythroid 
progenitors through inhibition of Foxa3a expression, which control genes associated 
with enucleation 102. In addition, it stimulates the translation of transcripts that are 
crucial for self-renewal division and is implicated in a host of other functions (reviewed 
in Stefanetti et al.103).
While EPO was pursued as the first recombinant hormone to stimulate erythropoiesis, 
other synthetic hormone agonists were already tested as a treatment for anemia. In 
certain cases, glucocorticoids, a class of lipophilic hormones, were reported to relieve 
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anemic patients of disease symptoms.104,105 Now these cases are all recognized to belong 
to Diamond Blackfan Anemia, where the curative effect results from increasing the 
output of stress erythropoiesis. In line with this, mice with low levels of glucocorticoid 
receptor (GR) expression do not show a direct erythroid phenotype, yet fail to mount 
a sufficient stress response.106–108 Upon stimulation by signaling molecules nuclear 
hormone receptors, such as the GR, dimerize to bind specific sequences in the DNA 
and activate gene expression of their targets, either alone or in cooperation with other 
regulators like those from the KLF family or NF-E2.109
While the balance between pro-survival and pro-apoptotic signals in essential for the 
progression of erythropoiesis, the combination of SCF and EPO is sufficient to recreate 
the process in vitro, and is enhanced by glucocorticoids. A description of other soluble 
factors is therefore beyond the scope of this introduction. 
Erythroid niche
Although soluble factors are considered the main source of signaling in cultures of 
erythroid cells, in vivo these signals make up only part of the erythroid niche. For example, 
membrane-bound SCF is a component that is required for erythropoiesis in vivo.89
The dissection of bone marrow that led to the description of the different stages of 
erythroid development also resulted in the identification of another central component 
of the niche for definitive erythropoiesis: the erythroblastic islands. These structures 
consist of central macrophages surrounded by different terminal differentiation stages 
of erythroid progenitors, as many as 30 around 1 macrophage in humans. 110–112 Cells in 
these structures can adhere to each other via a range of surface molecules, including 
erythroid macrophage protein (Emp), VCAM-1, ICAM-4, α5 integrin and α4-β1 (for review 
see Heideveld and van den Akker113). 
Since the discovery of this part of the erythroid niche, the interaction with a central 
macrophage has been implicated in taking up the expelled nuclei, positively influencing 
erythroblast survival and contributing to iron uptake (reviewed in Manwani and Bieker114). 
Despite the range of functions that have been attributed to the interaction between 
erythroblasts and macrophages, the importance of the macrophage is still not fully 
understood. In part due to contradictory result with macrophage inhibition; depletion of 
macrophages by clodronate does not result in an overt erythroid phenotype. In contrast, 
a KO-model for Maea, encoding erythroid macrophage protein (EMP), is embryonic 
lethal at d12.5 with a severe anemic phenotype.115,116The embryonic lethality suggests 
the importance of the erythroblast island in the expansion of definitive erythropoiesis 
in the fetal liver. Interestingly, in fetal liver macrophages KLF1, master regulator of 
erythropoiesis, has been implicated in the upregulation of DNAse II, the enzyme that 
facilitates the breakdown of expelled nuclei after uptake by the macrophage.117 
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Like their mouse counterparts, central macrophages in human bone marrow can be 
characterized by the expression of CD169 and VCAM-1. Protein and mRNA analysis of 
patients with anemia, or after HSC transplantation have suggested a role for EMP in 
the human erythroblastic island, by showing upregulation of Emp in response to EPO 
treatment.118 Recent RNA-sequencing experiments show that next to surface markers 
CD169, Emp and VCAM-1 mouse bone marrow and fetal liver macrophages express 
higher levels of the Epo receptor119 In addition, molecules involved in iron recycling 
are expressed at higher levels in EpoR positive macrophages compared none EpoR 
macrophages, which would support the notion of their importance in erythropoietic 
support and possible regulation of the interaction by erythroid hormones. 
In vitro approaches underline the role of macrophages in erythroid support.120,121 Next to 
controlled co-cultures of isolated erythroblasts and macrophages, the interaction is also 
modelled in human erythroid cultures started from peripheral blood monocytes (PBMC). 
There the CD14+ monocyte fraction obtains a phenotype similar to that described for 
central macrophage in response to glucocorticoid stimulation, becoming CD163, CD169 
and CD206 postive. Interestingly, these same cultures show that the CD14+ fraction 
positively influence the yield about 5-, to 10-fold by promoting progenitor survival.122,123 
Combined this shows the potential of cells to interact in a niche environment and 
influence gene expression at various stages of development. 
The above paragraphs illustrate how the differentiation process is influenced by the 
signals a cell receives from its surroundings. Each of these signals is relayed via signaling 
cascades, or direct activation of transcription modifiers, that in turn form complexes 
with other proteins that affect different layers of regulation, which were discussed 
in the previous section. Our ability to combine and integrate these observations is 
continuously increasing, as we will see in the final part of the introduction. 
Data on hemoglobin switching: recent years
In the preceding paragraphs we’ve seen how the knowledge on hemoglobin switching 
developed from the discovery of red blood cells, through discovery of normal and 
abnormal globin chains, to various layers that control regulation of gene expression. In 
the process the hemoglobin switching field developed into a well-established model for 
developmental gene regulation in a multi-gene locus. Even though the core regulatory 
mechanisms of gene expression from the locus have been identified, the exact sequence 
of events that initiates each developmental globin switch remains to be elucidated. 
Since the hemoglobin genes and their regulators make up only a minute portion of 
the genes that change during erythropoiesis, a possible explanation would be that a 
yet to be identified factor that initiates the switching process. Indeed, new regulatory 
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factors have been added to the globin switching model in the recent years, as will be 
discussed later in this section. 
Another explanation could be that we have yet to describe the interplay between 
regulation of gene expression at different organizational levels. At cellular level, the 
previous sections on erythroid signaling and the niche described how interaction 
between cells affects regulation of gene expression via direct cell-cell contact or via 
soluble signaling molecules. These signaling events have to converge at the different 
layers of regulation of gene expression, as the combination of transcription factors 
with the DNA sequence and chromatin structure controls gene expression at the 
level of the genome. Assuming that developmental erythropoiesis can be modeled 
as a deterministic process, each of the regulators involved in globin switching could 
potentially be affected by signals from the higher organizational level. A more extensive 
model of regulating gene expression during developmental erythropoiesis might help 
capture the interactions that drive developmental globin switching. 
Historically, pioneering discoveries in each time period were guided by the ability 
to observe and describe the phenomena of interest with the new technologies of that 
time, be it the earliest microscopy in the discovery of red blood cells, electrophoretic 
shift assays for the different hemoglobin types or molecular cloning at the basis of all 
genetic components. Often, interdisciplinary efforts shaped not only new assays, but 
also new language to observe and describe the basis for new hypotheses. 
Today, in order to deal with the higher complexity of expanded regulatory networks, 
biology and computer science are increasingly interconnected. They provide the basis 
for assays that simultaneously measure different layers of regulation at a genome 
wide scale; at the genome level with genome wide association studies (GWAS), at the 
chromatin level with ATAC sequencing, at transcript level with mRNA sequencing, or at 
protein level with proteomics.
By combining more elaborate data collection and improved methods to uncover 
patterns in data, the hemoglobin switching field is primed for further discoveries that 
lead to alternative treatments in hemoglobinopathies. The last chapter of this thesis 
will discuss this premise in more detail. 
As an advance on this discussion, the second part of the introduction will borrow 
techniques from the field of natural language processing and network analysis to 
interpret the literature on hemoglobin switching from the last two decades. It will 
compare two ten-year periods and outline how the work in this thesis extended from 
the developments in these recent years and the general progress of the field described 
in the previous paragraphs.
Figure 4 summarizes the most frequently occurring words in the titles of publications 
for the search “hemoglobin switching” on Web of Science in the last two decades (see 
boxed text). The most frequent words in the titles capture a shift of focus in the field. 
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The period from 1999 –2008 shows “locus” as top term followed by “beta” and “gamma” 
and terms like “alpha”, “control” and “region” most frequently used after that. The period 
2009 –2018 also shows “beta” and “gamma”, but now “bcl11a” and “klf1” are the most 
frequent terms that follow. Both periods also mention either “transgenic” or “mouse”, 
“model” to highlight the importance of experimental systems. 
The main trend captured in the word frequency analysis reflects the transition from 
DNA structure of the beta-locus to individual transcription factors as the central topics in 
publications on globin gene regulation. Along with the main components of each trend, 
its main implication towards the development of novel treatments will be discussed in 
this second part of the introduction.
Figure 4. Word cloud summarizing most frequent terms in publication titles from ten-year time 
periods. Top panel period 1998 –2008. Bottom panel 2009-2018
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Locus control over the hemoglobin switch
As noted in the historical overview, the locus control region was discovered as a 
collection of DNAse I hypersensitive elements that conveyed erythroid-specific 
chromatin accessibility and copy-number dependent expression levels to linked globin 
genes, irrespective of the integration site of the DNA vector 49. The different elements 
that make up the LCR and interacting proteins, including SPI1/KLF1, GATA1 and NF-E2, 
and DHS interaction were identified early on.52,124–127 Yet, exactly how the LCR contributed 
to globin expression remained an outstanding question. 
The working hypotheses included mechanistic models such as chromatin looping, 
gene competition, gene silencing and RNA polymerase II tracking. As more components 
of globin gene regulation were described these were found to be non-mutually exclusive 
(reviewed by Bank128). The central place of the terms “locus”, “control” and “region” in 
the text analysis of the 1999-2008 period results from a high number of publications 
that described the experimental evidence of chromatin looping and its place in gene 
regulation. These elaborated how folding the 3D-chromatin structures, would place 
the LCR in close proximity to the promoters of the different globin genes in order to 
recruit transcription factors that co-regulate transcription of different globin genes. The 
hypothesis was fueled by the observations of alternating proximity of the LCR between 
beta- and gamma-globin promoters in RNA in-situ hybridization assays 129. Following 
this observation, experiments with the mouse Hbb locus provided direct evidence 
for distal interactions in vivo. Using the newly developed Chromosome Conformation 
Capture (3C) technique; in fetal liver derived erythroid cell the LCR region was found in 
close proximity to the active Hbb genes in the locus, in a structure that was termed the 
Active Chromatin Hub (ACH), while Hbb locus was found in a linear conformation in brain 
cells. The interaction in the ACH results in looping out of the 30-50kb chromatin stretch 
between the active globin promoters and the LCR and are specific to the developmental 
stages in both mouse and human cells. Early developmental stages show ACH formation 
with the fetal globin genes, looping out the chromatin fiber with the adult stage globin 
genes.65,130,131
Forced chromatin looping
KLF1 and GATA1 were among the first transcription factors that were reported to drive 
ACH formation or contribute to the stabilization of the structure.132,133 The formation of 
an ACH exemplifies how both the DNA sequence, transcription factors and 3d-structure 
interact in regulation of gene expression. The importance of transcription factors in this 
process has since been validated in experiments with artificial zinc fingers linked to LIM 
domain binding 1 protein (LDB1), that were able to reactivate fetal globin expression in 
adult erythroblasts, or by introduction of a KLF1 binding site in silenced HBG promoter that 
induced expression of fetal hemoglobin in HUDEP2 cells.134–136 Both these experiments 
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A network approach to analysis of publication data
Along with our understanding of molecular and developmental mechanisms, the amount of scientific 
papers has increased exponentially in the last decade. Much like the cross-over from physic’ information 
providing the basis for molecular biology, approaches borrowed from computer sciences can help 
detect structures in bodies of literature. Here a combination of natural language processing (NLP) and 
network analysis are combined to illustrate an alternative approach to literature review. 
Data collection
Literature search was performed on Web of Science with the term “(hemoglobin OR haemoglobin) 
AND (switch) AND (fetal OR gamma OR mice)” and was applied to two periods of ten years, 1999-2008 
and 2009-2018. The search term was created in an iterative process of trial and error with addition 
of, or adaptation to terms to yield a coherent set of publications on the hemoglobin switch. Only 
scientific articles were included to capture a process of spreading hypotheses through direct citation 
of experimental work. 
Network analysis 
Network analysis can be an intuitive to visualize connections between neurons, people, products or 
other concepts the analysis is performed on. In the case for publications on the hemoglobin switch, 
a network was constructed using first author name and publication year as an identifier for each 
publication. Publication that were cited at least twice were combined with the reference list from each 
publication to form the initial network, that was then pruned to only include nodes that were cited by 
at least two others in the network. Velocity (number of citations per year) was included to highlight 
influential papers within cliques of the network, which in turn served as the backbone for the discussed 
literature in the second part of the introduction.
Natural language processing
NLP revolves around allowing computers to interface, process and ultimately understand bodies of 
text. At its basis a bag of word approach first quantifies word frequencies. For the publications in the 
network the titles were split into individual words that are counted. Further processing was used to 
subtract stop words and most frequent co-occurring words between the two time periods analyzed. 
This latter step prevents the overlapping terms from obscuring differences in topics by general terms 
like “hemoglobin” or “erythropoiesis”.  For the resultant dataset most-frequent words were plotted in 
word clouds.
Inherent bias from selection
Each of the described steps introduces considerable biases, be it in the choice of database and search 
term, the inclusion criteria for two or more citations for inclusion of publications in the network, or 
filtering of n most frequent words. In more advanced application of this type of literature research 
multiple searches could be combined across databases to reduce bias there.
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demonstrate the ability of the LCR to activate silenced globin genes through changing 
transcription factor binding to sites in the silenced promoters. Although these studies 
provide proof of concept for induction of HbF expression through forced chromatin 
looping, other genetic engineering approaches for treatments of hemoglobinopathies 
are at more advanced stages of the development process. 
Targeting DNA sequences
The understanding of the locus layout and structure has resulted in clinical trials where 
hemoglobin genes are introduced in patients with sickle cell disease or β-thalassemia. 
The virus vectors, used to introduce the transgenes, exploit a conformation similar to 
the original mini locus that conveyed position independent gene expression.137,138 
Lentiviral vectors with a globin transgene linked with different assortments of the LCR 
hypersensitivity sites were tested for their efficacy (reviewed in Cavazzana et al139). 
Ultimately, this led to the development of the GLOBE, BB305 and βAS3-FB for clinical 
testing.140–142 At their core these vectors contain the HS2, 3 and 4 elements from the 
locus control region linked to an HBG gene or a modified HBB gene, that prevents 
sickling of cells increasing treatment efficacy in sickle cell patients. These vectors have 
been successfully introduced in patient stem cells that upon transplantation to relieve 
patients from their need for blood transfusion. The initial result are promising and a 
number of clinical trial is still under execution (for review see Carden and Little143, Telen 
et al144). Although this shows the power of using gene therapy to treat patients with a 
β-locus defect. The requirement for transplantation of modified stem cells, make broad 
scale application less feasible, particularly in countries with the highest incidence of 
beta-hemoglobinopathies. 
Transcriptional regulation of hemoglobin switching
EKLF or KLF1 also shows up as a frequent term in both the ’98-’08 and the ’09-’18 period 
(figure 4). As noted earlier in the introduction, it was one of the first lineage-specific 
transcription factors to be directly implicated in the control of adult globin expression 145. 
In addition to regulation of the globin genes, its role as a master regulator of erythropoiesis 
was discovered half way through the nineties. From there the mechanisms by which it 
can control the various processes were starting to be elucidated, as a result KLF1 
shows up as one of the most frequent terms in the text analysis on the ’98-’08 period 
(Figure 4, top panel). 
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KLF1 as a looping factor
Evidence for the importance of KLF1 in erythropoiesis in general and hemoglobin 
switching in particular came from the Klf1 knockout mouse model which displays 
embryonic lethality at embryonic day 12.5 due to impaired differentiation of definitive 
erythroid cells. 54,55 The same mouse model was used to identify KLF1 as an important 
factor in establishing chromatin looping between the Hbb locus and its LCR. Through 
its three zinc finger domains KLF1 recognizes CACCC-motifs.145 Both the LCR HS3 and 
the Hbb promoters contain such sequences, which allow KLF1 binding and formation of 
the ACH. Klf1 knockout mice show no interaction between these sites and only express 
embryonic beta-like globin chains.132 Combined with the observation that introduction 
of a KLF1 binding site in the HBG1 promoter, mimicking the British HPFH genotype, 
induces γ-globin expression136, discussed in the previous paragraph, this established the 
importance of KLF1 as a looping factor.
KLF1 as a co-factor
Next to the ability to establish an ACH at the Hbb locus, KLF1 regulates erythropoiesis 
as co-factor in different complexes. It can facilitate direct transcriptional activation 
or initiation by interaction with core transcription machinery TFIIH and TAF9. At the 
same time, it has been suggested to interact with epigenetic remodeling complexes, 
including NuRD, P300/CBP, SWI/SNF and Sin3A/HDAC, that would at allow KLF1 
directed complexes to convey activating or repressive states on the chromatin at target 
loci.146,147 Despite limited evidence for presence of KLF1 in these complexes, (spatie)post-
translational modifications to KLF1 have been described to provide a mode through 
which transcriptional regulation can be altered. 
Post-translational modifications to KLF1 are found throughout both the proline-
rich protein interaction domain and the zinc-fingers, which suggests that different 
parts of the protein are required for different regulatory functions. Examples of post-
translational modifications include ubiquitination to control KLF1 protein levels, 
phosphorylation to ensure activation, acetylation to interact with protein complexes 
and SUMOylation required for nuclear translocation (see review by Yien and Bieker148). 
Further importance of posttranslational modifications and nuclear localization of KLF1 
has been demonstrated in the interaction between KLF1 and Friend of EKLF (FOE). 
FOE-knockout mice show altered nuclear localization of KLF1. While timed activation 
of protein kinase c (PKC) and the subsequent phosphorylation of KLF1 at the serine 
residue 68 (S68) was demonstrated to affect binding to FOE and importin-β1.149
The notion that specific regions of the protein are important for different aspects 
regulation of gene expression, is supported by a wide range of erythroid phenotypes 
that result from KLF1 variants.
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KLF1 variants and HPFH
While the publications on hemoglobin switching in the ’98-’08 period described the role 
of KLF1 in chromatin looping and transcription factor complexes, the high frequency of 
KLF1 in the more recent period results from publications that described various variants 
of KLF1 that were discovered in association with HPFH and a range of other erythroid 
phenotypes. A recent review describes how the advent of genetic screening in patients 
with different erythroid phenotypes has identified over 65 variants of KLF1 since 2010. 
In total the authors describe over 140 variants, that are divided over 4 classes ranked 
on the severity of the resultant phenotype. The lower classes included mild phenotypes, 
like HPFH, aberrant blood group expression and milder forms of anemia, while a single 
variant in class 4 is linked to dominant congenital dyserythropoietic anemia (CDA type 
IV; see review by KLF1 consensus group150).
The identification of the p.K288X variant in a Maltese family with HPFH definitively 
linked KLF1 to fetal hemoglobin expression in humans. Individuals in this cohort were 
all compound heterozygous for the mutation, that targets the KLF1 mRNA from one 
allele for non-sense mediated decay, rendering these individuals haploinsufficient. The 
lower levels of KLF1 were suggested to result in lower levels of BCL11A, the direct 
repressor of γ-globin expression that will be discussed further on as a KLF1 target 
gene.151,152 While the HPFH individuals in this cohort shared the same KLF1 variant, they 
showed HbF phenotypes ranging from 18.5% to 3.5% of total hemoglobin.
Master regulator of erythropoiesis
The wide variety of erythroid phenotypes that present as a result of KLF1 variants 
illustrate the myriad of processes that it controls in erythropoiesis. To date roughly 700 
target genes, activated by KLF1, encode proteins that are involved in globin expression, 
heme synthesis, membrane and cytoskeleton integrity, metabolic processes and cell cycle 
regulation.132,153,154 Along with these studies, the Klf1 knockout mice show the central 
importance of KLF1 during terminal erythroid differentiation.
Prior to terminal erythroid differentiation KLF1 controls the balance between the 
megakaryocytic and erythroid lineages. Although the exact workings of this regulatory 
circuit are incompletely understood, it partly results from a counter balance with FLI1, an 
important megakaryocytic transcription factor that is expressed at higher levels in Klf1 
knockout embryos and is downregulated upon KLF1 overexpression.155,156 Next to the 
ability of KLF1 and FLI1 to interact in vitro, competition for limiting amounts of GATA1 
as co-factor has been suggested as a possible mechanism for the cross-antagonism 




The induction of HbF following the introduction of a KLF1 binding site in the HBG1 
promoter serves as an example how targeted approaches can exploit the role of KLF1 as 
a looping factor at the level of DNA sequences.136 This type of approach is yet to reach 
the clinical testing phase, but potentially provides a gene therapy that is less prone to 
off-target effects of genetic manipulation by for example random integration of gene 
vectors that carry repaired beta-locus. 
At the level of protein complexes, targeting KLF1 is an interesting candidate, because 
many of its variants share HPFH as a phenotypic trait.150 Potentially, targeting specific 
regions of the protein might alter expression of the globin genes, without affecting 
other target genes. However, the central role of KLF1 in erythropoiesis and the wide 
variety of phenotypes observed in humans carrying KLF1 variants suggests that such 
an approach could come with undesirable side effects. In this light, identification of the 
mechanism by which specific variants of KLF1 induce HPFH, without affecting erythroid 
characteristics, remains of particular interest.
KLF1 targets repress HBG
While KLF1 by itself affects globin gene expression by influencing chromatin looping, it 
has a more pronounced effect through two of its target genes. This is reflected in the text 
analysis from the most recent decade, where KLF1 shows up as the main term together 
with BCL11A, a direct repressor of γ-globin expression (Figure 4 bottom panel).
Figure 5. Schematic representation of KLF1 associated transcription factors bound across the HBB 
locus in adult conformation. 
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BCL11A
The importance of BCL11A was discovered in a GWAS study that showed the association of 
the BCL11A locus with HPFH.159,160 Since then extensive characterization has established 
BCL11A as a direct repressor of γ-globin expression57, which is reflected by the high 
number of article on BCL11A in the text analysis of the most recent period (figure 4B). 
During the characterization process, various mechanisms for repression by BCL11A 
have been put forward. It was shown to interact with hematopoietic regulators, including 
SOX6 and GATA1, and binds to Nucleosome remodeling domain (NuRD) complexes, 
via interaction with CDH3/4, MDB2 or MDB3 and histone deacetylases 1 and 2.161,162 
In turn NuRD sub-complexes containing GATAD2A, HDAC2, MBD2, MTA2 and CDH4 
where recently found to be essential for repression of HbF.163 Recent insight in to the 
mechanism of repression by BCL11A comes from ChIP and cut-and-run sequencing 
experiments, which confirmed that BCL11A binding the –114 site in the HBG promoters. 
While the early characterization of BCL11A binding partners, like NuRD suggests that 
the repression by BCL11A results from the direct recruitment of epigenetic modifying 
complexes to these regions, the localization at the promoter also inhibits the formation 
of a stable chromatin loop of between the LCR and upstream regions of the globin 
genes.134,164–166 
LRF
The most recent addition to the regulatory network of γ-globin does not show up in 
figure 4 as it was only recently described for its role in the hemoglobin switch. 
Leukemia related factor, LRF, which is encoded by the ZBTB7A gene, represses γ-globin 
independently of BCL11A, by affecting the histone density at the HBG genes.56 Like 
BCL11A it is a KLF1 target, it is found in MDB2 complexes, but binds a different site 
located at –200 in the HBG promoters.164,167 Next to the repression of γ-globin expression, 
LRF has pleiotropic effects in lineage specification, oncogenesis and metabolic processes 
(see review by Constantinou168). For example, in preventing cell death via inhibiting 
expression of pro-apoptotic BCL2 (BIM) to prevent cell death during terminal erythroid 
differentiation.169 
Like for KLF1, therapeutic potential for direct targeting of LRF is limited due to its 
role in regulating more general processes. Approaches would have to forego reducing 
levels of the protein and could instead focus on disrupting binding interaction within 
LRF NuRD complexes. 
Targeting KLF1 targets
Since its discovery BCL11A has been hailed as an ideal candidate for targeted therapy 
aimed at reactivating the HBG genes. Particularly, because there is limited evidence for 
lower BCL11A expression affecting erythroid characteristics apart from HbF induction and 
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the potential for erythroid specific targeting. Although its potential is supported BCL11A 
haploinsufficiency cases with curative levels of HbF, these cases are also associated with 
neurologic defects.170,171 Similarly mouse models for BCL11A deficiency show defects in 
B-cell lymphopoiesis and early hematopoietic development.172,173 
To limit the effects of BCL11A modulation outside of the erythroid lineage, therapy 
approaches use erythroid specific promoter in lentiviral constructs with short-hairpin, 
or micro RNA directed against BCL11A, or target the erythroid specific enhancer in the 
second intron of the gene for deletion via zinc-finger nuclease or CRISPR-Cas9.174–176 
Clinical trials using these approaches in combination with bone marrow transplantation 
are underway. 
Scope of this thesis
Hemoglobinopathies are the most common monogenic disorder today. As noted in 
earlier sections, studying the hemoglobin switch has a long history in trying to find 
alternative treatments to recurrent blood transfusion in anemias that result from these 
diseases.
The work presented in this thesis aims to identify novel therapeutic alternatives, 
through increasing understanding of gene regulation during erythropoiesis and 
hemoglobin switching. To this end we developed a model system for primary erythroid 
cultures, characterized the model with respect to HbF expression in vitro and applied 
the model to investigate the effect of KLF1 variants in human and mouse. 
In addition, future optimization and further development of the culture protocol and 
the corresponding culture medium can provide a basis for development of patient-
tailored transfusion products (chapter 2).
The culture system mimics conditions that are normally found under stress 
erythropoiesis. Previously this mode of erythropoiesis was linked to increased HbF 
compared to steady-state erythropoiesis in adults. While previous work on the culture 
system showed that the monocyte fraction attains a central macrophage phenotype 
upon stimulation with dexamethasone and positively influenced the yield in cultures 
started from PBMCs. Combined, the HbF expression and the role of the monocyte 
fraction in cultures led us to the question if cell-cell interactions influence expression 
of HbF in vitro (chapter 3). 
The range of KLF1 variants with a benign phenotype along with its central role 
in erythropoiesis make it an interesting target for studying both regulation of gene 
expression in general and the globin genes in particular. In the case of p.K288X variant 
in KLF1, present in a HPFH cohort from Malta, there is remaining variation in HbF 
levels that is not readily explained by the variant itself, or co-inheritance of other 
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variants of known HbF modifiers. The culture system from the first chapter was used 
to revisit the Maltese cohort to identify what drives the remaining variation between 
individuals with the p.K288X variant (chapter 4).
Although HPFH resulting from KLF1 variants commonly co-occurs with relatively 
mild erythroid phenotypes, the KLF1 p.E325K variant is an exception. The variant affects 
the highly conserved second zinc finger region and causes dominant severe congenital 
dyserythropoietic anemia. The Nan mouse model can be used to study the effect of a 
similar KLF1 variant. It carries a Klf1 allele with an E to D variant at the paralogous 
position in the protein. Previous work on this model suggests that the variant alters 
the transcriptional control of KLF1 over a specific group of target genes [Nebor 2018]. 
To what extent the variant influences the expression of the globin genes in early 
development has not been established. In addition to globin characterization in the 
earliest developmental stages, cultures of Klfwt/ Klfnan cells were performed to assess 
effect of the Nan variant on erythroid specification (chapter 5).
The general discussion of the thesis will discuss how the data generated in this 
thesis relates to existing insights on stress erythropoiesis, means for environmental 
signaling in an erythroid niche and how these observations could be used to increase 
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Abstract
Transfusion of donor-derived red blood cells is the most common form of cellular therapy. 
Donor availability and the potential risk of alloimmunization and other transfusion-
related complications may, however, limit the availability of transfusion units especially 
for chronically transfused patients. In-vitro cultured, customizable red blood cells would 
negate these concerns and further increase precision medicine. Large-scale, cost effective 
production depends on optimization of culture conditions. We developed a defined 
medium and adapted our protocols to GMP culture requirements, which reproducibly 
provided pure erythroid cultures from peripheral blood mononuclear cells without prior 
CD34+ isolation, and a 3x107-fold increase in erythroblasts in 25 days (or from 100 million 
PBMC, 2-4ml packed red cells can be produced). Expanded erythroblast cultures could be 
differentiated to CD71dimCD235a+CD44+CD117-DRAQ5- red blood cells in 12 days. More 
than 90% of the cells enucleated and expressed adult hemoglobin as well as the correct 
blood group antigens. Deformability and oxygen binding capacity of cultured red blood 
cells was comparable to in-vivo reticulocytes. Daily RNA sampling during differentiation 
followed by RNA-seq provided a high-resolution map/resource of changes occurring 
during terminal erythropoiesis. The culture process was compatible with upscaling using 
a G-Rex bioreactor with a capacity of 1L per reactor, allowing transition towards clinical 




Blood transfusion is the most applied cellular therapy, with more than 80 million 
transfusion units administered worldwide each year1. Inherent risks of donor-transfusion 
material are alloimmunization and presence of blood-borne diseases. Oxygen-carrier 
substitutes have shown to be applicable in case of immediate emergency but cannot 
replace long term blood transfusions2. The potential to culture red blood cells (RBC) for 
transfusion purposes has been recognized for a long time3-10. Transfusion medicine and 
the care of chronic transfusion patients with prophylactic antigen matching has already 
substantially decreased the rate of alloimmunization (<5%). There are many variables 
that result in alloimmunization, including access to centers who are molecularly typing 
both donors and recipients to precisely match the unit to the patient. Cultured RBC (cRBC) 
that are antigen-compatible will decrease the risk of alloimmunization in patients. Cost-
effective, large-scale culture of blood group matched RBC will provide a degree of donor 
independency and minimization of donor-patient blood type variation. In addition, cRBC 
can be used as vehicles for enzyme replacement therapy11, or as therapeutic delivery 
systems targeting specific body parts12. Several groups already cultured enucleated 
cRBC from cord blood CD34+ cells13-15. However, these cells produce fetal hemoglobin 
with a higher tendency to denature and to cause membrane damage compared to adult 
hemoglobin16. We have previously shown that enucleated cRBC can be generated starting 
from adult peripheral blood mononuclear cells (PBMC), a better accessible source than 
cord blood CD34+ cells and allows adult autologous cRBC17. Importantly, the erythroid 
yield from PBMC is 10-15 fold increased compared to CD34+ cells isolated from a similar 
amount of PBMC, due to support from CD14+ cells present in PBMC17-19. 
One transfusion unit contains about 2x1012 RBC, reflecting the high requirement for 
erythroblast expansion to obtain sufficient numbers of cRBC. Previous attempts to culture 
the required number of enucleated cRBC from CD34+ cells isolated from PBMC were 
hampered by low expansion or poor enucleation20,21. Expansion of CD71highCD235adim 
erythroblasts can be prolonged by exploiting the cooperative action of erythropoietin 
(EPO), stem cell factor (SCF) and glucocorticoids involved in stress-erythropoiesis in a 
serum/plasma-free environment7,17,18,22,23, while differentiation is induced by increasing 
concentrations of EPO and dispensing with SCF and glucocorticoids. Here, we describe 
a three stage GMP-grade culture protocol using culture dishes or G-Rex bioreactors, 
both with high expansion and enucleation to generate PBMC-derived cRBC. To this end 
we have developed a completely defined GMP-grade medium. This three-stage culture 
protocol can be used for small-scale GMP-grade production, yielding >90% enucleated 
reticulocytes with adult hemoglobinization. 
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Material and Methods
Cell culture 
Human PBMC from whole blood were purified by density separation using Ficoll-Paque 
(manufacturer protocol). Informed consent was given in accordance with the Declaration 
of Helsinki and Dutch National and Sanquin Internal Ethic Boards. PBMC were seeded 
at 5-10x106 cells/ml (CASY® Model TCC; Schärfe System GmbH, Reutlingen, Germany) 
in Cellquin medium based on HEMA-Def7,17 with significant modification (Table S1 lists 
all components) supplemented with erythropoietin (2U/ml; ProSpec, East Brunswick, 
NJ), human recombinant stem cell factor (100ng/ml; ITK Diagnostics BV, Uithoorn, The 
Netherlands), dexamethasone (1μM; Sigma, St. Louis, MO) and 0.1% human albumin (cHA; 
kindly provided by Sanquin Plasma Products, Amsterdam, The Netherlands, perturbation 
with albumin see Supplementary Material), referred to as Expansion Medium (EM). 
Interleukin 3 (IL3) was added (1ng/ml; Miltenyi Biotec, Bergisch Gladbach, Germany) 
to EM on the first day (stage I). Media was partially replenished every two days with 
EM. Around day 6, upon erythroblasts detection, the cells were maintained 1-2x106 
cells/ml for 15-25 days (stage II). Erythroblasts differentiation (stage III) was induced 
in Differentiation Medium (DM) containing Cellquin supplemented with erythropoietin 
(10U/ml), 5% Omniplasma (Octopharma, Wien, Austria), holotransferrin (700μg/ml; 
Sanquin) and heparin (5U/ml; LEO Pharma BV, Breda, The Netherlands). At day two, half a 
medium change was performed. At day 5, storage components (Sanquin Plasma Products, 
Amsterdam, The Netherlands) were added and media was refreshed (half) every two days 
until fully differentiated at day 10-12 of differentiation. For reticulocyte filtration see 
Supplementary Material.
Flow cytometry
Cells were washed and resuspended in HEPES buffer supplemented with 1% HA. Cells 
were incubated with primary antibodies for 30 minutes at 4 °C, measured on FACS Canto 
II or LSRFortessa (both BD Biosciences, Oxford, UK) and analyzed using FlowJo software 
(FlowJo v10, Ashland, OR, USA). Reticulocyte RNA was stained with Thiazole orange 
(TO; Sigma) as described previously Abcam, Cambridge, UK). Antibodies are listed 
in Supplementary Material., Cambridge, UK). Antibodies are listed in Supplementary 
Material.
RBC deformability
RBC deformability was measured by the Automated Rheoscope and Cell Analyzer (ARCA) 
as described previously25. 10 Pa shear stress was used and 3000 cells were measured 
and grouped in 30 bins according to increasing elongation or cell projection area (as 
a measure of membrane surface area). Both the extent of elongation (major cell radius 
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divided by minor cell radius) and the area (in mm2) was plotted against the normalized 
frequency of occurrence. 
HPLC
Culture lysates were prepared and stored at -80 °C prior to analysis as described 
previously25. In short, hemoglobin separation was performed by high performance cation 
exchange liquid chromatography (HPLC) on Waters Alliance 2690 equipment (Waters, 
Milford, MA, USA) using30min elution over a combined 20-200mM NaCl and pH7.0-
6.6 gradient in 20mM BisTris/HCl and 2mM KCN. A PolyCAT A 100/4.6mm, 3mm, 1500Å 
column (PolyLC, Columbia, MD, USA).
Coomassie
Ghosts (RBC membranes) were generated as described before26, subjected to SDS-PAGE 
gels (Bio-Rad, Hercules, CA, USA) and total proteins were stained with Coomassie brilliant 
blue. In short, proteins were fixed in 30% ethanol, 2% (v/v) phosphoric acid overnight, 
washed two times 10minutes in 2% phosphoric acid and equilibrate for 30min in 2% 
phosphoric acid containing 18% ethanol and 15% (w/v) ammonium sulphate. Gels were 
stained by diluting Coomassie Blue G-250 dissolved in water (0.2%) slowly to a final 
concentration of 0.02% (0.2mg/ml).
Cytospins
Cells were cytospun using Shandon Cytospin II (Thermo Scientific), dried and fixed in 
methanol. Cells were stained with benzidine in combination with the Differential Quick 
Stain Kit (PolySciences, Warrington, PA) (manufacturers protocol). Slides were dried, 
subsequently embedded in Entellan (Merck-Millipore) and covered with a coverslip. 
Images were taken using microscope DM2500 with 40x or 10x object (Leica DM-2500; 
Germany).
RNA-seq analysis
Erythroid cultures on differentiation medium were sampled daily for 12 days. 
Sequencing libraries were prepared using Trizol RNA isolation, cDNA amplification and 
rRNA depletion using HyperPrep Kit with RiboErase (KAPA Biosystems, Pleasanton, CA, 
USA) as described by manufactures. Reads were mapped to ChGR38.v85 and differential 
expression analysis was performed with EdgeR27. A detailed description can be found 
in Supplementary Material. 
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Figure 1. Efficient expansion of erythroblasts in plasma/serum-free GMP-grade medium. (A) PBMC were 
cultured towards erythroblasts in GMP-grade medium supplemented with EPO, SCF and Dex (EM) for 26 
days. Medium was prepared using either ultra-clean HA (cHA), detoxified HA (dHA), recombinant HA (rHA), 
Albuman® or plasma. Cell counts at day 0 were normalized to 1 PBMC at the start of culture. Cultures 
were kept at 0.7 to 2x106 by dilution. Symbols indicate mean fold-change at any day compared to 1 PBMC 
seeded, error bars indicate SD (n=4). (B) PBMC from 4 independent donors were cultured from PBMC in 
Cellquin medium (cHA) supplemented with EPO (2U/ml), SCF (100ng/ml) and Dex (1μM) in culture dishes 
until a pure erythroblast population was obtained (at day 7). Erythroblasts were further expanded in a 
G-Rex bioreactor or in culture dishes. Mean fold-change (± SD) was calculated and compared (two-way 
ANOVA, * P<0.05; n=4). (C) Representative dot plots indicating cell surface expression levels of CD71 
and CD235 in cultures as described in B. Quadrants are labeled (P1-P4) and relative cell numbers per 
quadrant indicated as percentage (D-E) quantification of percentages per quadrant in dot blots similar 
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Large-scale erythroblast expansion from PBMC using a G-Rex 
bioreactor and GMP-grade medium
To establish medium conditions to obtain and prolong erythroid expansion from adult 
PBMC, we first tested distinct sources of albumin. Different expansion media (EM, Table 
S1) with 0.1% ultra-clean human albumin obtained after plasma fractionation (cHA), 
2,5% plasma, 2,5% Albuman®, 0.1% detoxified Albuman (dHA), or 0.1% recombinant 
HA (rHA) were used (Figure 1A and Figure S1A). Plasma or Albuman® resulted in (i) 
low erythroblast yield, (ii) presence of non-erythroid cells (negative for CD71 and 
CD235) and (iii) premature differentiation of erythroblasts, indicated by a loss of CD71 
expression in conjunction with increased CD235a expression (Figure S1A)28,29. In contrast, 
EM supplemented with cHA, dHA, or rHA showed a significantly increased erythroid 
expansion potential with limited spontaneous differentiation and a complete absence of 
non-erythroid cells (Figure 1A and Figure S1A). Of note, PBMC contain primarily T-cells, 
myeloid cells and B-cells and only on average 0.16% CD34+ HSPC that are capable of 
differentiating into erythroid cells17,19. Therefore, expansion curves using PBMC as a 
starting material show a drop in expansion between day 0 and day 5, caused by a loss of 
these non-proliferating immune effector cells17,18. By consequence, a fold change increase 
of erythroid cells from PBMC of circa 105-fold corresponds to a circa 108-fold increase 
from the CD34+ cell compartment.
Large scale cRBC production in culture dishes is practically impossible. Therefore, 
a G-Rex bioreactor from Wilson Wolf Manufacturing (Saint Paul, MN, USA) was used 
in which a gas-permeable membrane at the bottom allowed proliferation in larger 
volume/surface conditions30,31. The G-Rex bioreactor does not support adherent cells, 
such as the CD14+ PBMC that promote erythroid yield by increasing CD34+ cell survival18, 
which compromises stage I yield (data not shown). Therefore, PBMC cultures were 
started in culture dishes/cell stacks until an erythroblast population was obtained 
around day 7 of culture in EM supplemented with cHA. Subsequently (stage II), cultured 
erythroblasts were either transferred G-Rex systems or retained in culture dishes and 
could be maintained for at least 26 days (Figure 1B). Transfer to a G-Rex bioreactor 
briefly delayed erythroid expansion but showed a similar expansion rate between day 
15 and 25. Although the G-Rex bioreactor yielded slightly less cells (3x106 vs. 3x107), 
less donor variation was observed. Erythroid cells can be staged from CD71highCD235dim 
erythroblasts (P1) to enucleated CD71-CD235+ reticulocytes (P4), with intermediate 
stages in which cells are characterized by increased CD235a and reduced CD71 
expression (Figure 1C)29. At day 7, no non-erythroid cells (CD71-CD235-) were observed, 
indicating a pure erythroid culture, (day 0 to day 7 culture progression was previously 
published by our laboratory18). During erythroblast expansion in stage II, erythroblasts 
52
Chapter 2 - Large-scale in-vitro production of red blood cells from human peripheral blood
gained expression of CD235a from day 10 onwards resulting in a pure population of 
CD71highCD235+ erythroblasts, that could be expanded for at least 26 days (Figure 1C-E 
and Figure S1A). Previously, we showed that these CD71highCD235+ erythroblasts, cultured 
in presence of Epo/SCF/Dex, express low levels of hemoglobin, and have a morphology 
overlapping pro-erythroblasts and basophilic erythroblasts. When using the general 
term ‘erythroblasts’ in this manuscript, we indicate this stage. Expansion of erythroblasts 
in EM medium limits their differentiation to CD71low polychromatic and orthochromatic 
erythroblasts to a small fraction of cells that escapes the differentiation block. During 
prolonged culture in EM spontaneously differentiating cells accumulate (figure 1C-E). 
Interestingly, cells expanded in the G-Rex system maintained a less differentiated state 
for a prolonged culture period (>16days), as shown by delayed CD235a upregulation 
and maintenance of high CD71 expression (Figure 1E). In conclusion, a defined GMP-
grade medium enabled pure erythroblast cultures from a mixed PBMC cell pool with 
significantly delayed onset of spontaneous differentiation, resulting in a large expansion 
potential in both culture dishes and a G-Rex bioreactor.
Erythroid cultures from G-Rex and normal culture dishes fully 
enucleate 
Differentiation of erythroblasts to polychromatic erythroblasts, orthochromatic 
erythroblasts, and eventually to enucleated reticulocytes (stage III) is induced by removing 
SCF and dexamethasone whilst increasing the EPO and holo-transferrin concentration 
and supplementing with 5% Omniplasma. Heparin is added to prevent medium from 
clotting (differentiation medium, DM). Erythroblast differentiation is characterized by i) 
a transient proliferation burst with decreased cell-cycle time resulting in a reduced cell 
volume, ii) hemoglobinization, iii) erythroid specific protein expression of e.g., blood group 
antigens, and iv) enucleation13,17,28,29,32. During the first days of differentiation, in particular 
in culture dishes, proliferation was observed followed by cell growth arrest (Figure 2A). 
Note that the number of cells after the initial short proliferation burst did not decrease, 
suggesting no negative effect on culture viability. In contrast, cells differentiated in a 
G-Rex bioreactor did not show increased expansion. 
During erythroblast differentiation, both erythroid cells cultured in dishes and the 
G-Rex system increased expression of CD235a and lost expression of CD71, although 
erythroblasts differentiated slightly faster in culture dishes (Figure 2B-D). Differentiation 
was accompanied with a decrease in cell size (FSC-A). Both CD71 and c-KIT (CD117) 
expression increased at day 1 followed by a sharp down regulation (Figure S2A-B). 
Furthermore, CD44 was progressively reduced in expression as reported before17. 
Although CD235 expression increases in early differentiation as cells become smaller 
it decreases slightly, which may be due to loss of membrane surface during enucleation. 
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Figure 2. Differentiation of erythroblasts in culture dishes or a G-Rex bioreactor. (A) Erythroblast 
cultures were established in culture dishes. Erythroblast were washed and reseeded at 1x106/ml 
in Cellquin medium supplemented with EPO (10U/ml), Transferrin (700μg/ml), 5% human plasma, 
and heparin (5U/ml) (Differentiation medium, DM) in culture dishes (closed symbol) or G-Rex (open 
symbol). Erythroblasts were differentiated for 12 days. Cell density was measured at days indicated. 
Mean cell numbers were calculated. Error bars indicate SD Cell expansion was compared by two-way 
ANOVA, *P<0.05, ***P<0.001, ****P<0.0001; n=4. (B) Representative dot plots indicating cell surface 
expression levels of CD71 and CD235 in cultures as described in A. Quadrants are labeled (P1-P4) 
and relative cell numbers per quadrant indicated as percentage (C-D) quantification of percentages 
per quadrant in dot blots similar to those shown in C. Error bars indicate SD (n=4) C: cells cultured in 
dishes. D: cells cultured in G-Rex 
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Factors that affect enucleation at the end of erythroid 
differentiation
At blood banks, RBC are stored in media that contain specific components protecting 
viability, which were not present in DM. Therefore, a specific storage component solution 
was added at day 5 of differentiation, when the first reticulocytes arose in culture. This 
increased the number and frequency of enucleated cRBC, particularly in the G-Rex 
bioreactor (data not shown). Nonetheless, initial differentiation experiments in the G-Rex 
system yielded low numbers of enucleated cells compared to culture dishes (Figure 
S3A). Importantly, EM is completely replaced by DM upon initiating of differentiation in 
dishes, whereas only 90% EM could be replaced with DM in the G-Rex system. Indeed, 
replacing 90% of the culture medium in dishes, resulted in a reduction of enucleation, 
compared to complete medium replacement (56% vs 85%; Figure S3B). Reduction of 
dexamethasone (from 1μM to 10nM) two days prior to differentiation induction did 
not affect enucleation (Figure S3D). However, SCF removal from the culture medium 
two days prior to differentiation in culture dishes increased enucleation 1.5-fold (56% 
vs. 85%; Figure S3C). This indicated that residual SCF at the start of differentiation 
negatively affects enucleation during terminal differentiation. Enucleation was observed 
from day 5 onwards, resulting in >90% enucleation after 12 days of differentiation in 
culture dishes and almost 85% enucleation in the G-Rex system (Figure 3A and Figure 
S3E). A slight difference in the ratio nuclei/cRBC between culture dishes and a G-Rex 
bioreactor was observed (Figure 3B). The flow cytometry data and cytospin images at the 
end of differentiation revealed pyrenocytes (nuclei encapsulated by plasma membrane) 
and some nucleated cells (Figure 3C, D and Figure S3E). Filtration using neonatal 
leucoreduction filters resulted in 99% removal of nuclei and remaining nucleated cells 
and yielded a homogenous population of enucleated cRBC that is comparable to native 
erythrocytes on cytospins (Figure 3C, D). Of note, these cRBC resemble late reticulocytes 
populations as previously observed by us19, 24. 
cRBC resemble mature reticulocytes 
Filtered cRBC displayed a spheroid morphology, indicative of a reticulocyte population 
(Figure 3C). Expression of the major membrane proteins α/β-spectrin, Band 3, protein 
4.1, protein 4.2 and GAPDH were comparable between cRBC from culture dishes and 
peripheral blood RBC (Figure 4A). Reticulocytes released from the bone marrow have a 
low deformability, which increases during maturation towards RBC33. Both cRBC cultured 
in culture dishes and the G-Rex system showed a deformability index comparable to late 
peripheral blood reticulocytes (Figure 4B).
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Figure 3. Efficient enucleation is observed after 10 days in differentiation medium. (A-C) enucleated cells 
and nuclei were measured by flow cytometry, using DRAQ5 DNA staining against size (forward scatter) 
as shown in C. (A) The percentage of enucleated erythroid cells was measured during differentiation 
in culture dishes (closed symbols) and a G-Rex system (open symbols). Error bars indicate SD (n=4) 
Comparisons were made by unpaired t-test. (B) Ratio of nuclei versus cRBC during differentiation 
in culture dishes or G-Rex (<1 means more cRBC than nuclei). Mean ± SD (unpaired t-test, *P<0.05, 
**P<0.01; n=3-4). (C) Enucleation percentages of 10 days differentiated erythroid cultures before and 
after passage through a leukoreduction filter. Q1=nuclei; Q2=nucleated cells; Q3+Q4=enucleated 
cRBC. (D) Cytospins of the samples analysed in C stained for hemoglobin with benzidine and general 
cytological stains. As comparison, cytospins of native peripheral blood erythrocytes are shown. 
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Table 1: Blood group analysis of peripheral blood RBC (RBC) and cultured RBC (cRBC) using flow 
cytometry.
BLOOD GROUP RBC 1 RBC 2 RBC 3 CRBC 1 CRBC 2 CRBC 3
A - - + - - +
B - - - - - -
RHD + + - + + -
RHE - + - - + -
RHC + - - + - -
RHE + + + + + +
RHC + + + + + +
K - - - - - -
K + + + + + +
KP-A - - - - - -
KP-B + + + + + +
LU-A - - - - - -
LU-B + + + + + +
P1 + - + + - +
S + - - + - -
S + + + + + +
FYA + - + + - +
FYB - + + - + +
JKA - + - - + -
JKB + - + + - +
M + - + + - +
N + + + + + +
Furthermore, cell pellets from cRBC turned dark red and HPLC data showed that cRBC both 
derived from G-Rex and culture dishes mainly express adult hemoglobin (HbA1 73.4% 
G-Rex vs. 62% dish; HbA2 2.1% G-Rex vs. 1.4% dish) and low levels of HbF (8.8% G-Rex 
vs. 7.1% dish; Figure 4C-D). In addition, hemoglobin oxygen association and dissociation 
rates of cRBC and peripheral blood RBC were similar at variable oxygen pressure (Figure 
4E). Blood group expression of the cRBC was assessed by flow cytometry and compared 
to the original donor RBC. Blood group expression was in complete agreement with 
the original donors (Table 1). The functional similarities between cRBC and peripheral 
blood RBC indicate that the three-stage culture model using culture dishes or a G-Rex 
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Figure 4. cRBC are highly similar to donor RBC. (A) Ghosts from cRBC and peripheral blood RBC were lysed and 
subjected to SDS-PAGE. Gel was stained with Coomassie and depicts the most abundant proteins in RBC membranes. 
(B) Deformability of cRBC was measured under shear stress by ARCA, which elongates cells and measures length 
over width as deformability parameter. Progressively maturating reticulocytes were isolated from peripheral blood 
(in order of maturation, R1: RNAhighCD71high, R2: blue squares; RNAhighCD71low, R3: blue circles; RNAhighCD71-, blue 
triangles; R4: RNAlowCD71-, blue diamonds; as described24) were compared with fully mature RBC (red curves) and 
filtered cRBC from normal culture dishes (thick green line) or the G-Rex bioreactor (thick blue line). Right bar graph 
represent the quantification of >1000 cells per culture condition. (C-D) Expression of hemoglobin variants was 
determined by HPLC in cRBC in culture dishes before filtering (C) or G-Rex after filtering (D). Hemoglobin variants 
are indicated; exact retention time is indicated for each peak. (E) Oxygen association and dissociation curve for 
peripheral blood RBC (teal and red) and cRBC cultured in a G-Rex bioreactor (blue and green). The percentage 
oxygenated hemoglobin is measured at a gradient of oxygen tension given in Torr (upper line x-axes) and kPa (lower 
line x-axes).
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Terminal differentiation of erythroblasts to enucleated 
reticulocytes completely changes the transcriptome
Differentiation of non-hemoglobinized erythroid progenitor cells to functional enucleated 
cells involves significant changes in morphology, cell volume and protein content. 
Identification of regulatory processes is crucial to enhance and optimize the production 
and the yield of in-vitro erythropoiesis. A comparison of the in-vitro transcriptome 
to existing databases of in-vivo transcriptomes allows to benchmark the in-vitro 
differentiation process. Differentiation was started from CD117+CD71+CD235-/dimCD44high 
early erythroblast populations (phase III, day 0) from four distinct donors and daily RNA 
samples were collected until terminal enucleation state at day 12 (95%; Changes in 
surface marker expression in Figure S2). In reference to the early erythroblast population 
(day 0) 75% of the analyzed transcripts changed during differentiation (7792 transcripts 
with a FDR < 0.01 and fold-change > 4) with 5189 down regulated, 2726 upregulated 
and 124 that were transiently up- or downregulated (Figure 5A and Table S2). These 
major transcriptome alterations occurred primarily during the first 6 days (phase III). The 
expression of transcripts encoding proteins crucial for the function and immunological 
properties of RBC can be scrutinized. Figure 5B shows that RNA expression of different 
blood group antigen bearing proteins from these donors is differentially regulated over 
time. In addition, globin subunit expression dynamics indicated rapid hemoglobinization 
during the first 72 hours of differentiation coinciding with increased CD71 expression. 
Note that expression of beta globin subunits is significantly higher compared to gamma 
globins (FS5A). cKIT RNA was rapidly downregulated and CD235 (GPA) rapidly upregulated 
in agreement with flow cytometry results (Figure S5A). In line with the major transcriptional 
changes over the course of differentiation, principal component analysis (PCA) captured 
~57% of variance in the 2000 most variable genes. The first component associated with 
differentiation progression, sequentially grouping samples from subsequent days (Figure 
5C). Cultured RBC showed good functional and morphological correspondence with in-
vivo RBC (Figure 4). This raised the question how the cultured cells would compare to 
ex-vivo cells at the transcriptome level. Comparing published transcriptomes of bone 
marrow megakaryoid/erythroid progenitors (CD38+CD34+CD10-CD45RA-CD123-CD90-) 
and CD71+CD235+ erythroblasts34 to in-vitro cultured erythroid cells revealed that the ex-
vivo MEP grouped before the sequence of cultured cells, while the CD71+CD235+ grouped 
along with the cultured cells, with the same marker expression (Figure S4B). Note that 
the in-vitro cultures showed little variation between donors indicating a reproducible 
synchronized differentiation process. 
Ex-vivo cells showed relatively more variation in the PCA, which may be a consequence 
of the more broadly expressed erythroid surface markers used to isolate these cells. 
The major differences between cultured and ex-vivo cells accounted for 18% of the 
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Figure 5. RNA expression profiles during in-vitro erythroid differentiation are similar to ex-vivo isolated 
erythroid precursors. RNA was isolated at subsequent days of differentiation to identify changes in the 
transcriptome (4 independent donors) (A) Bars represent the number of transcripts that are up- (red) 
or downregulated (blue) each day in reference to the start of the culture (FDR < 0.01 and log fold 
change > 2,  or < -2). Lines reflect cumulative number of unique genes differentially expressed over 
the time course. (B) Heatmap of z-transformed expression values (log2-CPM) for all genes encoding 
for blood group antigens and or blood group bearing moieties. (C) The transcriptome of MEP (black 
squares) and CD71highCD235high erythroblasts (black circles) isolated from bone marrow was compared 
to the transcriptome of differentiating cRBC using principle component analysis (PC1 versus PC3).  (D) 
A Pearson correlation matrix of all samples used in panel A-C. (E-F) Mean transcript levels (transcripts 
per million mapped reads) were compared between MEP and cRBC day0 (E); and between freshly 
isolated erythroblasts and cRBC day3 (F).  
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expressed genes indicated that ex-vivo MEP were most similar to erythroblasts cultured 
under expansion conditions (d0) whereas ex-vivo CD235+CD71+ erythroblasts were 
most similar to d3 differentiated polychromatic erythroblasts (ρ = 0.89 and ρ = 0.85 
respectively, Figure 5D). Direct comparison of RNA expression between the ex-vivo 
MEP and d0 erythroid cells, and of the CD235+CD71+ ex-vivo erythroblast and d3 
differentiated cells showed comparable transcript levels (Figure 5E-F). Overall, the main 
difference between cultured and freshly isolated cells originates from genes that were 
predominantly expressed at increased levels in cultured cells compared to ex-vivo cells 
(Table S3). Of note, transcripts with increased expression in cultured cells were further 
downregulated upon differentiation progression in line with decreased expression 
observed in the more asynchronous ex-vivo erythroid cells (Figure S4B). Removing the 
low expression filter also revealed a set of 380 genes expressed at lower levels in 
cultured cells, that consisted of pseudogenes and transcripts encoding mitochondrial or 
ribosomal proteins (Table S4), probably reflecting a difference in technical processing of 
samples. The similarities in the transcriptome of cultured cells and the related stage in-
vivo indicates that close recapitulation of transcriptional changes is at the basis of the 
functional and morphological characteristics of the cultured erythroid cells. 
Discussion
Widescale clinical application of cRBC is faced by several constraints, like the inability to 
generate large cell numbers that are required, the high costs of ill-defined media and the 
low yield of enucleated, biconcave cRBC35. The culture protocol presented here challenges 
these constraints by boosting advances with respect to high enucleation rates, matching 
erythroid characteristic at different levels, redefining medium composition and maximum 
expansion without the necessity to first isolate CD34+ cells (Figure 6). Using a defined 
medium and exploiting stress erythropoiesis we achieve 107-fold erythroblasts expansion 
within 26 days. Despite starting from total PBMC, pure erythroid cultures expressing 
CD71 and CD235adim are obtained validating the GMP-grade medium yielding similar 
cell numbers as previously reported using commercial Stemspan media17,18. Using total 
PBMC not only allows outgrowth of all CD34+ progenitors, but also CD34- hematopoietic 
progenitors present in blood that have the capacity to differentiate towards erythroid 
cells17,18. Glucocorticoids are essential for stress erythropoiesis in the mouse and synergy 
of glucocorticoids with EPO and SCF induces erythroblasts proliferation whilst inhibiting 
differentiation7,23,32,36,37. The addition of glucocorticoids also supports erythropoiesis 
by differentiating peripheral blood monocytes or CD34+ cells to erythroid supporting 
macrophages during culture from PBMC, further increasing the erythroid yield19,38. In 
contrast to our plasma/serum-free expansion, many large-scale red cell culture protocols 
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use glucocorticoid agonists in combination with serum and/or plasma during expansion. 
Here, we showed that the addition of plasma causes premature differentiation of 
erythroblasts also in the presence of glucocorticoids9,10,13,39,40. Increased spontaneous 
differentiation upon addition of plasma during erythroblast expansion may be due to 
additional growth factors or other plasma components. Optimal expansion in absence 
of plasma/serum is important to reach the amount of cRBC required for transfusion, 
but also to establish erythroid cultures from small blood aliquots of specific anemic 
patients. We have recently shown that 3ml of blood is sufficient to culture enough cells 
to reprogram erythroblasts to induced pluripotent stem cells (IPSC)41. In addition to direct 
use, the expanded erythroblast can be frozen and defrosted without loss of expansion 
potential (data not shown), similar to what we previously reported for starting cultures 
from frozen PBMCs42. This introduces flexibility concerning actual production of products, 
for example with the generation of IPSC form cryo-preserved patient material43-45. The 
use of adult PBMC also facilitates the availability of starting material and introduces the 
possibility to culture autologous cRBC. This is important considering alloimmunization 
caused by blood group mismatches and matching from cord blood derived RBC may be 
complicated in either conventional transfusion or with novel therapeutic blood products. 
The culture process was compatible with up-scaling for clinical studies and applications 
using a G-Rex bioreactor. The G-Rex bioreactor allowed for 3x106 fold expansion per 
PBMC (~1x109 fold from CD34+ cells in these PBMC; taken the accepted 0,16% of CD34+ 
cells present in total PBMCs [heideveld, 2015]). Of note, we have submitted cells that 
have been expanded for 10 and the maximum of 25 days to differentiation (DM) and 
found that enucleation and differentiation progression is unperturbed (data not shown). 
Remaining nuclei and enucleated cells after differentiation could be efficiently removed 
using a leukoreduction filter, as generally employed by bloodbanks, to obtain a pure 
cRBC population. The total costs of one 5 liter GREX producing around 4.5ml GMP-grade 
cRBC from 100 million PBMC (roughly 80ml of blood) is approximately 28000 euros and 
would take 27 days (15 days of EM and 12 days of DM). Of note, it would take roughly 
36 days (24 days EM and 12 days DM) to culture a transfusion unit starting from 100 
million PBMCs. Two of the major challenges, besides bioreactor development, that need 
to be tackled are i) reducing prices of major cost drivers and ii) increasing the efficiency 
of filters as currently approximately 30% of cRBC can be recovered from the leucocyte 
filters. Costs can be significantly reduced if specific major cost drivers were to be produced 
in a bulk recombinant manner (e.g. growth factors). For instance, the recombinant GMP-
grade SCF, one of the major cost drivers in our protocol, presently is around 3500 times 
more expensive compared to insulin. Exchange of human albumin by novel agents like 
polyvinyl alcohol that have been shown to promote HS(P)C expansion could potentially 
cut costs significantly49. Also, novel cell permeable iron chelators that could be used as 
replacement for transferrin may cut costs. It has been estimated that around 5-10ml of 
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erythrocytes will be needed for specific therapeutic delivery of cargo. Thus, currently the 
costs to produce this amount, taking a filter efficiency of 30%, would be between 80.000-
200.000 euros. Considering expensive enzyme replacement therapies, the costs of in vitro 
cRBC may be competitively priced. However, it is clear that additional optimization and 
cost-reduction is needed as well as research into loading and stability of therapeutics 
within the in vitro cultured cells.
The defined IMDM-based culture medium, termed Cellquin, solely contains GMP grade 
components and finds its basis in HEMA-def7. Knowing the exact concentrations of all 
components within Cellquin now allows to quantitatively track erythroid requirements 
by combining the transcriptome/proteome with metabolomics. This may help to culture 
cells at higher densities and to cater specific media components exclusively erythroid 
need, leading to considerable cost-reduction and aiding upscaling. currently, the costs of 
Cellquin is lower compared to commercially available media, while performing at least 
similar.  
One Cellquin component paramount to its effectiveness is albumin. We observed that 
the isolation and manufacturing process of human albumin critically influences the 
erythroid expansion potential. Using ultra-clean, detoxified, or recombinant additive-free 
HA significantly increased the erythroid expansion potential. Albumin binds substances 
including proteins, metabolites and fatty acids, including toxins, drugs and other 
therapeutics46-48. Replacing ultra-pure cHA in EM by Albuman® reduced erythroblast 
expansion potential, which could be reverted by charcoal and ion exchanger treatment 
of Albuman®. Interestingly, the process to manufacture Albuman® includes a saturation 
step to restrain the albumin binding potential, rendering it mostly inert. This suggests 
that the binding and/or transport function of albumin is important to ensure continued 
erythroblast expansion. 
The technical improvements to the culture protocol result in excellent yield of in-vitro 
cultured erythroblasts combined with >90% enucleation, adult hemoglobin expression, 
correct blood group expression, deformability and oxygen saturation dynamics similar to 
donor peripheral blood enucleated cells. In addition, we present the first transcriptomic 
analysis from erythropoiesis originating from stress-erythropoiesis cultures. Comparison 
of this dataset to datasets from ex-vivo erythroid cells shows that, next to similarities in 
RBC characteristics, the cRBC are comparable to similar ex-vivo cells at transcript level. 
These observations together, make the transcriptome dataset provided here a valuable 
resource to address erythroid regulatory mechanisms. 
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Figure 6. Progression of erythroid cells during culture. Overview of the three-phase erythroid culture 
system using culture dishes or a G-Rex bioreactor. A pure erythroblast culture is established in dishes 
from PBMC during the first 7 days. From day 7 erythroblasts are expanded in G-Rex or in dishes. When 
transferred from expansion to differentiation medium, erythroblasts in dishes or in G-Rex can mature 
to enucleated cells. The small remnant of nucleated cells and nuclei (pyrenocytes) can be removed by 
passage through a leucocyte filter. The growth factors and hormones used in culture are indicated at 
the lower half of the graph.
In 2011, Timmins et al. demonstrated an ultra-high yield of cRBC with >90% enucleation 
from cord blood-derived CD34+ cells in the absence of plasma15. This reported erythroid 
yield was similar to our serum/plasma-free adult PBMC-derived erythroid expansion. 
However, >90% enucleation during terminal differentiation using our differentiation 
protocol (stage III) was only recapitulated in presence of plasma. Where, adding 5% 
Omniplasma increases enucleation from 20-25% to more than 90% (data not shown). 
Whether this reflects a difference in cord blood versus adult erythroid cultures remains 
unknown but important to investigate along with identifying the components in plasma 
that are key to this increased enucleation in our system.
Combined the advances of the presented protocol facilitate both easy implementation 
in other laboratories and study of erythropoiesis in healthy individuals or in patients 
of which limited sample volumes are available. It adds to the feasibility of using 
adult peripheral blood as starting material for cRBC cultures, which is an important 
step towards precision medicine. For example, in using custom engineered cRBC as 
cargo vesicles for drug delivery. In addition, the synchronized cultures contain young 
reticulocytes that have a theoretical lifespan of about 120 days. Chronic anemia patients 
that receive blood transfusions every two months may benefit from transfusions with 
in-vitro cultured long-lived RBC, potentially increasing the time between transfusions 
and thereby reducing the costs. Currently we are working towards a clinical trial that 
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Supplementary methods and material
Cell culture using different sources of human albumin
EM medium was supplemented with human bovine albumin (HSA) from different 
sources: Albuman® (Sanquin, Amsterdam, The Netherlands), detoxified HSA1, recombinant 
HSA (Akron Biotech, Boca Raton, FL, USA), or AB+ pool plasma (Sanquin) at indicated 
concentrations as specified in the figure legends. In addition, the commercial medium 
Stemspan (Stem Cell Technologies, Germany) was used 2.
RNA-sequening
Erythroblasts were allowed to differentiate to enucleated reticulocytes as described in 
culture protocol and summarized in figure 6. Cells were collected daily; RNA was isolated 
using Trizol (Invitrogen Technologies, Carlsbad, CA) and amplified and rRNA depleted 
using HyperPrep Kit with RiboErase (KAPA Biosystems, Pleasanton, CA, USA) as described 
by manufactures. 
Samples were sequenced at 30 million 75bp paired-end reads. After quality control 
with FastQC, read were mapped to genome ChGR38.v85 using STAR 3. Lowly expressed 
genes were filtered from count data, after correction for library size (counts per million 
mapped reads < 3). Subsequent differential expression analysis was performed with 
EdgeR using a paired design for individual donors and quasi-likelihood F-test to test 
expression at each day compared to day 0 4. The differential expression threshold was 
set over 4-fold difference and an FDR < 0.01. 
The comparison of cRBCs to ex-vivo cells was performed on samples aligned to ChGR38.
v85 with Salmon 5. This aligner allows for direct mapping to transcript isoforms, including 
these in the comparison while facilitating normalization to transcript length prior to 
plotting. Counts were normalized for transcript length and library size, as transcript per 
million mapped reads (TPM) and were plotted using ggplot2 package in R 6. 
Culture filtration to obtain reticulocytes
CRBC were purified using a 60ml neonatal leucoreduction filter (Haemonetic BV, Breda, 
The Netherlands). The filter was primed with IMDM containing 4% Omniplasma. Cultured 
cells were filtered followed by a 2 times wash with 25ml priming medium. CRBC were 
resuspended in IMDM containing 4% Omniplasma. Cells were centrifuged at 1600rpm for 
5 min in order to obtain packed red blood cells.
Flow cytometry
Antibodies used: Acris (Herford, Germany): anti-CD235a (FITC 1:400; PE 1:400); BD 
Biosciences: anti-CD117 (PE 1:50), anti-CD235a (PE 1:150); eBioscience (Vienna, Austria): 
anti-CD44 (APC 1:150); Miltenyi Biotec: anti-CD71 (APC 1:100; VioBlue 1:200), anti-
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CD235a (VioBlue 1:200); and Life technologies (Carlsbad, CA, USA): anti-CD117 (FITC 
1:100). The following antibodies were used for blood group analysis: IBGRL research 
products (Bristol, UK): anti-A (Bric145; 1:1000), anti-B (BGRL2; 1:500), anti-M (clone 
6A7; 1:5000), anti-N (clone BRIC157; 1:1000); Sanquin Products (Amsterdam, The 
Netherlands): anti-RhC (clone MS24; RBC 1:1000, cRBC undiluted), anti-Rhc (clone MS35; 
1:200), anti-RhE (clone MS260; RBC 1:80, cRBC undiluted), anti-Rhe (clone MS21/63; RBC 
1:100, cRBC undiluted), P1 (clone P3NIL100; 1:500), Kp-a (undiluted), kp-b (undiluted), 
Jk-a (MS15; undiluted), Jk-b (MS8; undiluted), Fy-a (P3TIM; undiluted), Fy-b (undiluted), 
Lu-a (undiluted), Lu-b (undiluted); Merck-Millipore (Darmstadt, Germany): anti-K (MS59; 
1:50), anti-k (P3A118OL67; 1:100), anti-s (P3Y326Bn5; 1:400). Ortho Clinical Diagnostics 
(Buckinghamshire, UK): anti-S (MNS3; undiluted). Anti-A, B, N, M were detected with an 
anti-mouse IgG FITC-labeled antibody (Life Technologies; 1:200) was used and anti-C, c, 
E, e, Jk-a, Jk-b, and P1 with an anti-human IgM PE-labeled antibody (Southern Biotech, 
Birmingham, AL; 1:500). The remaining blood groups were detected with an anti-human 
IgG PE-labeled antibody (Southern Biotech; 1:200).
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Figure S1. The presence of plasma/serum affects erythroblast expansion. (A) Representative dot plots 
of erythroblasts at day 12 of culture in EM in the presence of ultra-clean HSA (cHSA) or EM in which 
cHSA was replaced by plasma, Albuman® or detoxified HSA (dHSA) corresponding to Figure 1A (n=3-
4). Note that the percentage of immature erythroblasts (P1) is 3-4 times higher in cHSA and dHSA 
compared to plasma and Albuman®. This suggests that cHSA and dHSA prolong the immature state 
of erythroid cultures. (B) Erythroblasts cultured in EM for 18 days in the presence of cHSA, dHSA or 
recombinant HSA (rHSA) showed a similar expansion potential. Mean ± SD (two-way ANOVA; n=2). (C) 
Erythroblasts at day 7 and 19 of expansion in Stemspan, as described previously2.
A
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Figure S2. Marker expression during erythroblast differentiation in culture dishes. (A) Erythroblasts 
were cultured in EM for 8 days and subsequently differentiated for 12 days in DM. Representative 
overlaying histograms showing the FSC-A during differentiation and the expression levels of CD71, 
CD235a, CD117 and CD44 analyzed by flow cytometry. (B) Graphs corresponding to panel A showing the 
mean fluorescence intensity (MFI; n=4). (C) Lines depicts RNA expression over days of differentiation 
(log2 transformed CPM) for differentiation markers CD71 (transferrin receptor, TFRC) and CD235 
(glycophorin A, GYPA) along with c-kit(SCF receptor, KIT) adult globin subunits (HBB and HBA2) and 
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Figure S3. Enucleation of cRBC derived from culture dishes or a G-Rex bioreactor. (A) Graph showing 
the enucleation of erythroid cells during differentiation after supplementation into DM to initiate 
differentiation in a G-Rex bioreactor, compared to culture dishes corresponding to Figure 2E. Mean 
± SD (paired t-test, *P<0.05, **P<0.01, ***P<0.001; n=4). (B) Erythroblasts expanded and differentiated 
in culture dishes with 90% (unwashed) or 100% (washed) replacement of expansion medium before 
differentiation medium. Mean ± SEM (paired t-test, **P<0.01; n=4). (C) Two days prior to differentiation 
in DM, SCF was either removed from or maintained in EM and enucleation was analyzed after 12 days 
of differentiation. Mean ± SEM (paired t-test, ****P<0.0001; n=4). (D) Two days prior to differentiation 
1000nM or 10nM dexamethasone was added to the expansion medium. Expansion medium was 
replaced with differentiation medium and cells were analyzed for enucleation after 12 days. Mean ± 
SEM (paired t-test; n=4). (E) Representative dot plots of erythroblasts during differentiation in DM in 






Figure S4. Variation between cRBC and ex-vivo cells. (A) Plot of cRBC and ex-vivo cells on first and 
second component of PCA. (B) Line plot shows expression levels for transcripts higher expressed in 
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Abstract
Haploinsufficiency for transcription factor KLF1 causes a variety of human erythroid 
phenotypes, such as the In(Lu) blood type, increased HbA2 levels, and hereditary 
persistence of fetal hemoglobin. Severe dominant congenital dyserythropoietic anemia 
IV (OMIM 613673) is associated with the KLF1 p.E325K variant. CDA-IV patients display 
ineffective erythropoiesis and hemolysis resulting in anemia, accompanied by persistent 
high levels of embryonic and fetal hemoglobin. The mouse Nan strain carries a variant 
in the orthologous residue, KLF1 p.E339D. Klf1Nan causes dominant hemolytic anemia 
with many similarities to CDA-IV. Here we investigated the impact of Klf1Nan on the 
developmental expression patterns of the endogenous α-like and β-like globins, and the 
human β-like globins carried on a HBB locus transgene. We observe that the switch from 
primitive, yolk sac-derived, erythropoiesis to definitive, fetal liver-derived, erythropoiesis 
is delayed in Klf1wt/Nan embryos. This is reflected in globin expression patterns measured 
between E12.5 and E14.5. Cultured Klf1wt/Nan E12.5 fetal liver cells display growth- and 
differentiation defects. These defects likely contribute to the delayed appearance of 
definitive erythrocytes in the circulation of Klf1wt/Nan embryos. After E14.5, expression of 
the embryonic/fetal globin genes is silenced rapidly. In adult Klf1wt/Nan animals, silencing 
of the embryonic/fetal globin genes is impeded, but only minute amounts are expressed. 
Thus, in contrast to human KLF1 p.E325K, mouse KLF1 p.E339D does not lead to 
persistent high levels of embryonic/fetal globins. Our results support the notion that 
KLF1 affects gene expression in a variant-specific manner, highlighting the necessity to 




KLF1 is an erythroid-specific transcription factor with diverse and essential roles during 
terminal erythroid differentiation1. Cloned from mouse erythroleukemia cells it was 
initially called erythroid Krüppel-like factor (EKLF) in honor of its erythroid-specific 
expression and DNA-binding domain2. This domain is composed of three Cys2-His2 zinc 
fingers similar to those found in the Drosophila Krüppel transcription factor. KLF1 is the 
founding member of the KLF branch of the 27-strong SP/KLF family3. Despite the fact that 
other SP/KLF factors such as SP1, SP3, KLF2, KLF3 and KLF8 are abundantly expressed 
in erythroid cells4, 5, gene inactivation in mice demonstrated that KLF1 is essential for 
definitive erythropoiesis6, 7. Specifically, activation of β-globin expression was strongly 
impaired leading to a severe β-thalassemia phenotype. Restoring globin chain imbalance 
with a human γ-globin transgene failed to rescue the embryonic lethality of KLF1 
deficiency8, indicating that other KLF1 target genes contribute to the erythroid defects. 
This was confirmed by genome-wide expression analyses which established that KLF1 is 
involved in virtually every aspect of terminal erythroid differentiation9-12. In humans, the 
first KLF1 variants reported were identified as the molecular basis of the rare blood type 
In(Lu)13. In all cases one normal KLF1 allele was present showing that, similar to Klf1wt/
ko mice6, 7, this is sufficient to sustain erythropoiesis. These observations were extended 
by the discovery that KLF1 haploinsufficiency caused hereditary persistence of fetal 
hemoglobin (HPFH) in a Maltese pedigree14. To date, over 140 different KLF1 variants 
have been reported, and these have been linked to a broad range of hitherto unrelated 
human red cell disorders1. In Sardinia, Thailand and southern China the frequency of 
KLF1 variants reaches endemic proportions, e.g. 1.25% in southern China15. In these 
populations cases with compound heterozygosity for KLF1 variants occur16-18. In such 
cases one allele invariably carries a missense variant which retains partial activity. KLF1 
compound heterozygotes display more pronounced phenotypes including HbF levels of 
>20%16-18, persistence of embryonic globins18, microcytic hypochromic anemia16, 18, and 
pyruvate kinase deficiency18. One case of a KLF1 null neonate was reported19. This infant 
displayed severe non-spherocytic hemolytic anemia with elevated HbF levels (>70%). 
Thus, the vast majority of KLF1 variants displays classical autosomal recessive inheritance, 
and KLF1 haploinsufficiency is associated with mild erythroid phenotypes. The exception 
is a KLF1 variant in which an ultra-conserved residue in the second zinc finger is affected. 
This KLF1 variant, p.E325K, causes congenital dyserythropoietic anemia, type IV (CDA-IV; 
OMIM613673)20-22. CDA-IV patients suffer from severe hemolytic anemia, splenomegaly, 
elevated HbF, iron overload, and dyserythropoiesis. Notably, the mouse neonatal anemia 
(Nan) phenotype is caused by a variant of the orthologous residue in mouse KLF1, 
p.E339D23, 24. Klf1Nan displays semi-dominant inheritance. Klf1wt/Nan animals suffer from 
hemolytic anemia while Klf1Nan/Nan embryos die around embryonic day 10.5 (E10.5) due 
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to failure of primitive erythropoiesis23, 24. This phenotype is more severe than that of 
Klf1ko/ko embryos which die around E14.5 due to failure of definitive erythropoiesis6, 7. 
During definitive erythropoiesis KLF1Nan is thought to exert a dominant-negative effect 
on the function of wildtype KLF123, 24. In primitive erythropoiesis, KLF1 and KLF2 have 
compensatory roles25 and the early lethality of Klf1Nan/Nan embryos could therefore be 
due to interference of KLF1Nan with normal KLF2 function. In addition, KLF1Nan leads to 
aberrant gene expression which exerts negative effects on erythropoiesis26, 27.
In human HBB locus transgenic mice, the fetal HBG1/2 genes are expressed highly in 
primitive erythrocytes and early definitive erythrocytes. Switching to expression of the 
adult HBB gene occurs in the fetal liver between E12.5 and E14.528. Given the profound 
deregulation of embryonic and fetal globin genes in CDA-IV patients, we investigated 
expression of the α-like and β-like globins in Klf1wt/Nan mice carrying a single-copy 
human HBB locus transgene29 at embryonic, fetal and adult stages of development.
Methods
Animals
All animal studies were approved by the Erasmus MC Animal Ethics Committee. Mouse 
strains used were Klf1wt/Nan (C3H101H-Klf1Nan/H30) crossed with PAC8.1 mice carrying a 
single-copy human HBB locus transgene (Tg(HBB)8.1Gvs29). For details see Supplementary 
Materials and Methods.
Culture of mouse erythroid progenitors
E12.5 fetal livers were disrupted and single cell suspensions were cultured as described31. 
For details see Supplementary Materials and Methods.
RNA isolation and RT-qPCR analyses
RNA was extracted using TRI reagent (Sigma-Aldrich). For details see Supplementary 
Materials and Methods. 
Flow cytometry analysis
Single-cell suspensions were washed twice with PBS and resuspended in FACS buffer 
(PBS containing 1% (w/v) bovine serum albumin, 2 mM EDTA). Approximately 106 cells 
were incubated for 30 minutes at room temperature with the appropriate antibodies. 
Data were acquired on a Fortessa instrument (BD Biosciences), and analyzed with FlowJo 




Cell morphology was analyzed using cytospins stained with May Grünwald-Giemsa 
(Medion Diagnostics) and O-dianisidine (Sigma-Aldrich)32. Pictures were taken with 
a BX40 microscope (40x objective, NA 0.65) equipped with a DP50 CCD camera and 
Viewfinder Lite 1.0 acquisition software (all Olympus).
Statistical tests
Statistical analysis of gene expression data was performed by using Mann-Whitney tests 
(GraphPad Prism). Excel 2010 was used to draw the graphs. Standard deviations and 
p-values <0.05 are displayed in the relevant figures (*).
Results
Expression patterns of the globin genes in Klf1wt/Nan mice
To assess the impact of KLF1Nan on developmental regulation of globin gene expression, 
the Klf1wt/Nan strain30 was crossed with PAC8.1 mice carrying a single-copy human HBB 
locus transgene29. RT-qPCR analysis was performed to determine α-like and β-like globin 
expression in Klf1wt/wt::HBB (control) and Klf1wt/Nan::HBB (Klf1wt/Nan) embryos at E11.5, E12.5, 
E13.5, E14.5 and E16.5. Primer pairs were designed to amplify the mouse and human 
embryonic, fetal and adult globin mRNAs specifically, aiming to minimize inter-globin 
and inter-species cross-reactivity. Of note, the human HBG1 and HBG2 genes, encoding 
Aγ- and Gγ-globin respectively, arose by a recent duplication event and expression of 
these genes is assessed by a single primer pair. The same is true for the mouse Hba-a1/
Hba-a2 genes, encoding α1- and α2-globin respectively, and Hbb-b1/Hbb-b2 genes, 
encoding βmajor- and βminor-globin respectively (see Supplementary Information). Thus, 
we measured expression of mouse α-like globins (z and α1/2), mouse β-like globins (ey, 
βh1 and βmajor/minor) and human β-like globins (e, Aγ/Gγ, and β). For reasons of clarity 
we will refer to mouse α-like globins as mz and mα, mouse β-like globins as mey, mβh1 
and mβ, and human β-like globins as he, hγ, and hβ in the remainder of this paper.
Globin gene expression patterns during development
The first erythroid cells are derived extra-embryonically from the blood islands in the yolk 
sac. They enter the circulation in the embryo proper after E8.5 as large nucleated cells 
referred to as primitive erythrocytes33. Expression of embryonic globins is a distinctive 
hallmark of primitive erythrocytes. The first intra-embryonically derived erythrocytes 
appear in the circulation around E12.5. These enucleated cells are generated in the fetal 
liver and referred to as definitive erythrocytes. They are characterized by predominant 
expression of adult globins; unlike the human HBB locus the mouse Hbb locus does not 
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harbor fetal β-like globin genes. Nevertheless, mice carrying human HBB locus transgenes 
have been extensively used to study fetal-to-adult hemoglobin switching34. 
To analyze the developmental dynamics of globin expression in Klf1wt/Nan embryos, we 
determined the globin expression profiles in RNA isolated from yolk sacs and fetal livers 
harvested between E11.5 and E16.5. Both the yolk sac and the fetal liver contain tissue 
cells plus circulating blood cells. First, we assessed expression of mβ-like globins. At 
E11.5, both the yolk sac and the fetal liver of control mice contained mainly mey globin, 
reflecting the presence of primitive erythrocytes in the circulation and the fact that the 
fetal liver only just starts to produce definitive erythroid cells (Figure 1AC). In E12.5 
fetal liver the production of large numbers of definitive erythroid cells was reflected in 
the dominant expression of mβ, while mey still constituted >90% of mβ-like globins in 
the yolk sac (Figure 1AC). At E13.5, expression of mβ-like globins detected in yolk sac 
was 70% mey and 30% mβ, whereas >95% of fetal liver mβ-like globin was mβ. Finally, 
mainly mβ was detected in fetal liver and yolk sac from E14.5 onward (Figure 1AC). In 
comparison, Klf1wt/Nan yolk sac and fetal liver expressed a larger fraction of mey at both 
E12.5 and day E13.5 (Figure 1BD). The increase of mβ expression over time is delayed in 
Klf1wt/Nan yolk sac and fetal liver (Figure 1BD), indicating a delayed shift in expression of 
primitive to definitive mβ-like globins. 
Figure 1. Developmental expression patterns of mouse β-like globins in control and Klf1wt/Nan embryos. 
Expression of mey, mβh1 and mβ was determined by RT-qPCR. Data are displayed as fraction of total 
mβ-like globin (mey+mβh1+mβ) expression. Embryonic day (E) and number of embryos (N) are indicated. 




Figure 1. Developmental expression patterns of mouse b-like globins in control and Klf1wt/Nan embryos 
Expression of mey, mbh1 and mb was determined by RT-qPCR. Data are displayed as fraction of total mb-like 
globin (mey+mbh1+mb) expression. Embryonic day (E) and number of embryos (N) are indicated. Asterisks 
indicate p-values<0.05; error bars indicate standard deviations. 
Next, we investigated whether this delay is specific for the Hbb locus, or 
whether it also occurs in the Hba locus. Yolk sacs and fetal livers from E11.5 control 
embryos expressed mz as the major a-like globin, with ma contributing 25-30% to 
total a-like globin expression (Figure 2AC). At E12.5 ma became the dominant a-like 
globin in fetal liver, mz was gradually replaced in the yolk sac by ma at E12.5 and 
E13.5, with the major shift to ma expression completed by E14.5 (Figure 2A), 
corresponding with fetal liver output in circulation. A different pattern was observed in 
yolk sacs and fetal livers from Klf1wt/Nan embryos. Compared to the controls, at E11.5 the 
contribution of mz was increased at the expense of ma (Figure 2BD). At E12.5 and 
E13.5 there was no increase in ma globin expression in the yolk sac (Figure 2B), and 
the increase in expression of ma in fetal livers was reduced compared to control fetal 
livers (Figure 2BD). Thus, Klf1wt/Nan affects the developmental expression patterns of the 
mouse a-like and b-like globins in a very similar manner, displaying a delayed switch 




Next, we investigated whether this delay is specific for the Hbb locus, or whether it also 
occurs in the Hba locus. Yolk sacs and fetal livers from E11.5 control embryos expressed 
mz as the major α-like globin, with mα contributing 25-30% to total α-like globin 
expression (Figure 2AC). At E12.5 mα became the dominant α-like globin in fetal liver, 
mz was gradually replaced in the yolk sac by mα at E12.5 and E13.5, with the major shift 
to mα expression completed by E14.5 (Figure 2A), corresponding with fetal liver output 
in circulation. A different pattern was observed in yolk sacs and fetal livers from Klf1wt/
Nan embryos. Compared to the controls, at E11.5 the contribution of mz was increased at 
the expense of mα (Figure 2BD). At E12.5 and E13.5 there was no increase in mα globin 
expression in the yolk sac (Figure  2B), and the increase in expression of mα in fetal 
livers was reduced compared to control fetal livers (Figure 2BD). Thus, Klf1wt/Nan affects 
the developmental expression patterns of the mouse α-like and β-like globins in a very 
similar manner, displaying a delayed switch to expression of the adult genes.
Figure 2. Developmental expression patterns of mouse α-like globins in control and Klf1wt/Nan embryos. 
Expression of mz and mα was determined by RT-qPCR. Data are displayed as fraction of total mα-like 
globin (mz+mα) expression. Embryonic day (E) and number of embryos (N) are indicated. Asterisks 
indicate p-values<0.05; error bars indicate standard deviations.
Because CDA-IV patients display very high HbF levels20-22, we extended the observations 
on the mouse globins to the human β-like globin genes thus adding analysis of the 
developmental expression patterns of fetal-stage globin genes. The E11.5 yolk sac and 
fetal liver of control embryos expressed very similar ratios of he and hγ, while expression 




Figure 2. Developmental expression patterns of mouse a-like globins in control and Klf1wt/Nan embryos 
Expression of mz and ma was determined by RT-qPCR. Data are displayed as fraction of total ma-like globin 
(mz+ma) expression. Embryonic day (E) and number of embryos (N) are indicated. Asterisks indicate p-
values<0.05; error bars indicate standard deviations. 
 
Because CDA-IV patients display very high HbF levels20-22, we extended the 
observations on the mouse globins to the human b-like globin genes thus adding 
analysi  of the developmental expression patterns of fetal-stage globin genes. The 
E11.5 yolk sac and fetal liv r of control embryos expressed very similar ratios of he and 
hg, while expression of hb was very low (Figure 3A). Compared to the controls, E11.5 
Klf1wt/Nan yolk sac and fetal liver displayed a small but significant shift to he expression. 
Relatively increased he expression was also observed in Klf1wt/Nan E12.5 yolk sac and 
fetal liver (Figure 3BD). Next to the difference in he expression at E12.5, hb made up 
~75% of total hb-like globins in control- compared to ~43% in Klf1wt/Nan fetal liver. This 
apparent lag in switching to hb expression was also observed in Klf1wt/Nan E13.5 fetal 
liver, and in E13.5 and E14.5 Klf1wt/Nan yolk sacs (Figure 3BD). In control yolk sacs, 
expression of hb increased rapidly to ~35% at E13.5, with hg remaining the most 
abundantly expressed hb-like globin accounting for ~50% of the total output of the 
HBB locus (Figure 3A). 
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fetal liver displayed a small but significant shift to he expression. Relatively increased he 
expression was also observed in Klf1wt/Nan E12.5 yolk sac and fetal liver (Figure 3BD). Next 
to the difference in he expression at E12.5, hβ made up ~75% of total hβ-like globins in 
control- compared to ~43% in Klf1wt/Nan fetal liver. This apparent lag in switching to hβ 
expression was also observed in Klf1wt/Nan E13.5 fetal liver, and in E13.5 and E14.5 Klf1wt/
Nan yolk sacs (Figure 3BD). In control yolk sacs, expression of hβ increased rapidly to ~35% 
at E13.5, with hγ remaining the most abundantly expressed hβ-like globin accounting for 
~50% of the total output of the HBB locus (Figure 3A).
Figure 3. Developmental expression patterns of human β-like globins in control and 
Klf1wt/Nan embryos. Expression of he, hγ and hβ was determined by RT-qPCR. Data are displayed as 
fraction of total hβ-like globin (he+hγ+hβ) expression. Embryonic day (E) and number of embryos (N) 
are indicated. Asterisks indicate p-values<0.05; error bars indicate standard deviations.
Compared to control yolk sacs, expression of hγ in Klf1wt/Nan E13.5 yolk sacs was even 
higher at ~60%, with hβ expression also rapidly increasing but reaching a lower level of 
~25% of hβ-like globins (Figure 3B). At E14.5, The hγ:hβ ratio shifted to 4:96 in control 
yolk sacs, while in Klf1wt/Nan yolk sacs this ratio remained higher at 28:72 (Figure 3AB). At 
E16.5, hβ expression accounted for >97% of total hβ-like globin in all yolk sacs and fetal 
livers, showing that hemoglobin switching had quantitatively proceeded to the adult 
profile in both genotypes (Figure 3). We conclude that expression of he is maintained at 
higher levels in E11.5-E12.5 Klf1wt/Nan embryos. This is followed by a lag in switching to hβ 
expression, which favors expression of hγ, in E13.5-E14.5 Klf1wt/Nan embryos. Nevertheless, 




Figure 3. Developmental expre sion patterns of human b-like globins in control a d Klf1wt/Nan embryos 
Expression of he, hg and hb was determined by RT-qPCR. Data are displayed as fraction of total hb-like globin 
(he+hg+hb) expression. Embryonic day (E) and number of embryos (N) are indicated. Asterisks indicate p-
values<0.05; error bars indicate standard deviations. 
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Delayed appearance of definitive erythrocytes in the 
circulation of Klf1wt/Nan embryos
Having established that the shift from embryonic to fetal and adult globin expression 
is delayed in Klf1wt/Nan embryos, we investigated whether this could be due to a delay in 
embryonic development. The erythroid compartment changes dynamically during mouse 
development33, and any alterations in this dynamic would be reflected in globin expression 
patterns. Primitive erythrocytes originate in the yolk sac and are the sole erythrocytes 
in the circulation until E12.5, when the first definitive erythrocytes are released from 
the fetal liver. As fetal liver erythropoiesis gathers momentum, the majority of cells in 
the circulation are definitive erythrocytes by E14.5. In contrast to primitive erythrocytes, 
definitive erythrocytes enucleate before they are released in the circulation. We used 
this characteristic to determine the contribution of primitive cells to the circulation by 
making cytospins of peripheral blood collected from E14.5 and E16.5 control and Klf1wt/
Nan embryos. Compared to the controls, nucleated erythrocytes were more abundant in 
cytospins of Klf1wt/Nan blood. They were still easily detected in E16.5 cytospins of Klf1wt/
Nan blood, while such cells were virtually absent in control samples (Figure 4A). To assess 
the switch from primitive to definitive erythropoiesis, E14.5 cytospins were split in early, 
mid and late times of litter harvest (Figure  4B). Consistent with the previous results, 
we observed that the fraction of nucleated cells declined very rapidly at this stage of 
development, in the controls from ~0.34 at early E14.5 to ~0.01 at late E14.5, and in the 
Klf1wt/Nan samples from ~0.52 at early E14.5 to ~0.13 at late E14.5. Importantly, compared 
to the controls the fraction of nucleated cells remained significantly higher in the Klf1wt/
Nan samples in all E14.5 litters. 
Using a CASY cell counter, we determined the cell size distributions in E14.5 blood 
samples. In E14.5 control samples, the two peaks representing primitive (large) and 
definitive (small) cells are clearly separated (Figure  4C). In E14.5 Klf1wt/Nan samples, 
these two peaks are not clearly separated. The apparent continuum of cell sizes is in 
agreement with the rampant anisocytosis observed in the cytospins of E14.5 Klf1wt/Nan 
blood (Figure 4A). Finally, we sought to use flow cytometry as an orthogonal approach to 
determine the contribution of primitive erythrocytes to the circulation. In an attempt to 
better distinguish primitive from definitive erythrocytes, we performed flow cytometry 
using CD71 (transferrin receptor), Ter119, and CD9 (Tetraspanin) which is a marker for 
primitive erythrocytes35. Compared to the controls, expression of CD71 was slightly 
increased on Klf1wt/Nan E10.5 primitive cells (Figure 4D). This might indicate a delay in 
maturation, similar to what has been proposed for Klf1wt/ko reticulocytes36. Expression of 
Ter119 was virtually absent in E10.5 Klf1wt/Nan erythrocytes, while CD9 expression was 
strongly reduced (Figure 4D). At E14.5, CD9 was unable to distinguish primitive from 
definitive erythrocytes in Klf1wt/Nan blood; in contrast to E14.5 Klf1wt/wt blood where a 
distinct fraction of CD9+ primitive cells was observed (Figure 4D, arrow). Collectively, 
we conclude that the contribution of primitive erythrocytes to the circulation of Klf1wt/
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Nan embryos cannot be determined by flow cytometry using CD71, Ter119 and CD9 as 
markers. Despite these technical limitations, the analysis of blood samples is consistent 
with the notion that, compared to control embryos, the contribution of primitive 
erythrocytes to the pool of circulating erythrocytes in Klf1wt/Nan embryos is extended 
during development.
Figure 4. Analysis of blood from control and Klf1wt/Nan embryos. (A) Cytospins of E14.5 and E16.5 blood 
isolated from control (Klf1wt/wt) and Klf1wt/Nan embryos, stained with dianisidine and histological dyes 32. (B) 
Fraction of nucleated cells in blood isolated from control (Klf1wt/wt) and Klf1wt/Nan littermates at early, mid 
and late E14.5. Asterisks indicate p-values<0.05; error bars indicate standard deviations. N=3 for each 
genotype at each developmental time point. (C) Cell size analysis of E14.5 and E16.5 blood isolated 
from control (Klf1wt/wt) and Klf1wt/Nan embryos, obtained with a CASY instrument. (D) Histograms of flow 
cytometry analysis of blood isolated at E10.5 and E14.5 from control (Klf1wt/wt) and Klf1wt/Nan embryos. 
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A) Cytospins of E14.5 a d E16.5 blood isolated from control ( lf1wt/wt) and Klf1wt/Nan embryos, stained with 
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blood isolated from control (Klf1wt/wt) and Klf1wt/Nan embryos, obtained with a CASY instrument. D) Histograms of 
flow cytometry analysis f bl od isolated at E10.5 and E14.5 from control (Klf1wt/wt) and Klf1wt/Nan embryos. Arrow 
indicates CD9+ primitive erythrocytes in Klf1wt/wt E14.5 blood. 
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Klf1wt/Nan erythroblasts display impaired proliferation and 
differentiation
The delays in hemoglobin switching and appearance of definitive erythrocytes in the 
circulation of Klf1wt/Nan embryos suggest that the production of definitive cells in the fetal 
liver might be affected by impaired proliferation or differentiation. Since KLF1 is critically 
involved in regulation of the erythroid cell cycle11, 37, 38, central to both these processes, we 
cultured primary cells derived from E12.5 fetal livers to assess the proliferative capacity 
of Klf1wt/Nan erythroblasts. RT-qPCR analysis at Day 6 of culture showed deregulated 
expression of the embryonic/fetal globin genes in the Klf1wt/Nan cells compared to the 
controls, demonstrating that this aspect of the phenotype is maintained in the culture 
system (Supplementary Table 1). We have previously shown that Klf1ko/ko E12.5 fetal 
liver cells expand well when grown under self-renewal conditions9. In contrast, Klf1wt/Nan 
erythroblasts from E12.5 fetal liver expanded very poorly under these growth conditions 
(Figure 5A). Up to Day 3-4 of culture, Klf1wt/Nan fetal liver cells expanded similar to those 
derived from control embryos. After Day 4, expansion of the Klf1wt/Nan cultures slowed down 
and the percentage of smaller cells increased, suggesting spontaneous differentiation. 
Consistent with previously reported RT-qPCR data of Klf1wt/Nan fetal liver RNA24, expression 
of cell cycle regulators E2F2, E2F4, and P18, all known KLF1 target genes11, 37, 38, was 
downregulated in Klf1wt/Nan cells compared to the controls, while expression of P21 was 
unchanged (Figure 5B). 
Next, the cells were switched to differentiation medium at Day 6. During differentiation 
the control cells, but not the Klf1wt/Nan cells, displayed the characteristic differentiation 
divisions, i.e. the cell number increased while cell size decreased (Figure 5CD). Cytospins 
taken at Day 2 of differentiation revealed many mature, enucleated and hemoglobinised 
cells in the control cultures (Figure 5Ea). Rare macrophages still present in the cultures 
were surrounded by healthy maturing erythroblasts (Figure 5Eb). Macrophage inclusions 
resembled nuclei, presumably resulting from phagocytosis of pyrenocytes (expelled 
erythroid nuclei33). In contrast, the Klf1wt/Nan cultures showed few enucleated cells and the 
cells displayed much larger nuclei (Figure 5Ec). Macrophages were not surrounded by 
enucleating erythroblasts, but appeared to engulf the entire erythroblast (Figure 5Ed). 
Combined these observations suggest that Klf1wt/Nan erythroblasts are impaired in both 
proliferation and differentiation.
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Figure 5. Erythroid progenitor cultures of control and Klf1wt/Nan E12.5 fetal liver cells. (A) Growth 
curves of primary erythroid progenitors cultured from control (Klf1wt/wt) and Klf1wt/Nan E12.5 fetal livers 
in StemPro medium containing SCF, Dex and EPO. (B) RT-qPCR analysis of cell cycle regulators in 
cultured erythroid progenitors (n=3 for each group). Asterisks indicate p-values<0.05; error bars indicate 
standard deviations. (C,D) Differentiation was induced on Day 6, transferring the cells to StemPro 
medium supplemented with EPO and transferrin. Cell number (C) and cell volume (D) was recorded. 
(E) At Day 2 of differentiation cells were centrifuged on glass slides, fixed and stained with dianisidine 
and histological dyes 32. (F) Flow cytometry analysis of cells cultured from control (Klf1wt/wt) and Klf1wt/
Nan fetal livers at Day 9 of culture. Cells were stained with antibodies indicated. The percentage of 
cells double-positive for the erythroid marker CD71 is shown on top, ± standard deviation. (nd): not 
detectable, due to the virtual absence of expression of myeloid markers on the control cells.
It is known that KLF1 blocks progression to myeloid lineages39. In the Klf1wt/Nan cultures 
we observed cells with morphological features of megakaryocytes (Figure  5Ee). Flow 
cytometry analysis of the cultured cells at Day 9 revealed that control cultures were 
essentially free of non-erythroid cells, while Klf1wt/Nan cultures displayed pan-myeloid 
markers on 20 to 50% of the cells (Figure 5F). Of note, the majority of these cells were 
positive for the erythroid marker CD71. Collectively, these data suggest that compromised 
lineage fidelity, reduced proliferative capacity and impaired terminal differentiation all 
contribute to the delay in abundance of definitive erythrocytes in the circulation of Klf1wt/
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It is known that KLF1 blocks progression to myeloid lineages39. In the Klf1wt/Nan cultures 
we observed cells with morphological features of megakaryocytes (Figure 5Ee). Flow 
cytometry analysis of the cultured cells at Day 9 revealed that control cultures were 
esse tially free of non-erythroid cells, while Klf1wt/Nan cultures displayed pan-myeloid 
markers on 20 to 50% of the cells (Figur  5F). Of note, the majori y of these cells were 
positive for the erythroid marker CD71. Collectively, these data suggest that 
compromised lineage fidelity, reduced proliferative capacity and impaired terminal 
differentiation all contribute to the delay in abundance of definitive erythrocytes in the 
circulation of Klf1wt/Nan embryos, thus bearing weight on the observed changes in globin 






Expression of globins in adult Klf1wt/Nan mice
The analysis of developmental expression patterns of the globins demonstrated that 
by E16.5 Klf1wt/Nan embryos had quantitatively switched to expression of the adult genes 
(Figures  1-3). However, it remains possible that the maintenance of embryonic/fetal 
globin silencing is perturbed in adult Klf1wt/Nan mice. Indeed, derepression of embryonic 
globin genes in the spleen of Klf1wt/Nan mice has been reported24. To investigate this further, 
we isolated RNA from spleen and bone marrow derived from control and Klf1wt/Nan mice. 
By RT-qPCR analysis we found that mz and mβh1, but not me, expression was increased 
between 35- to 800-fold in Klf1wt/Nan samples compared to control samples (Figure 6). For 
the human β-like globins, we observed 4- to 9-fold increased expression of he and hγ. In 
quantitative terms, even in the case of the most highly expressed embryonic globin mz, 
this amounted to less than 0.3% of total α-like globin. We conclude that maintenance of 
embryonic/fetal globin silencing is perturbed in bone marrow and spleen of adult Klf1wt/
Nan mice. Since the amount of embryonic/fetal globins produced remains below 0.3% of 
the total amount of globins, this is a qualitative rather than a quantitative trait.
Figure 6. Expression of human and mouse globins in bone marrow and spleen of adult control and Klf1wt/
Nan animals. Expression of mouse and human globins was determined by RT-qPCR. Expression ratios of 
individual globins in Klf1wt/Nan samples were calculated relative to those observed for the control 
samples (Klf1wt/wt). Note logarithmic scale of the y-axis. N=3 for each group. Asterisks indicate 
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Discussion
In humans, reduced KLF1 activity has been associated with persistent expression of fetal 
hemoglobin in adults1, 14. A severe phenotype of hemolytic anemia characterizes patients 
suffering from CDA-IV, caused by the p.E325K variant in the DNA binding domain of 
KLF1. In the Klf1wt/Nan mouse, the orthologous glutamic acid residue (p.E339) is changed. 
Biochemically, these amino acid substitutions are very different. In CDA-IV, the glutamic 
acid (E) is replaced by a basic amino acid (lysine, K) while in KLF1Nan it is replaced by 
aspartic acid (D), an acidic amino acid. Despite these biochemically opposing properties, 
the erythroid phenotypes of CDA-IV patients and Klf1wt/Nan mice share many similarities. A 
hallmark of CDA-IV patients is that they maintain high expression levels of embryonic and 
fetal globins. To investigate whether this is also the case in Klf1wt/Nan mice, we surveyed 
expression of the α-like and β-like globins during development. Our main observations 
are summarized in Supplementary Figure 1. We found that in Klf1wt/Nan embryos, switching 
from embryonic/fetal to adult globin genes is delayed in the endogenous Hbb and Hba loci, 
and in the single-copy human HBB locus transgene. Two mechanisms may contribute to 
this phenomenon. Firstly, decreased proliferation and differentiation of fetal erythroblasts 
delays the replacement of primitive by definitive erythroid cells. Since we isolated RNA 
from populations of cells, the ratio of primitive/definitive cells will have an impact on 
the globin levels measured. Secondly, although by E16.5 adult globins are quantitatively 
the dominant globins in Klf1wt/Nan embryos, the embryonic and fetal globin genes retained 
expression in adult spleen and bone marrow. Qualitatively, this persistent expression is 
another phenotypic similarity with CDA-IV patients. However, quantitatively there is a 
major difference. While in CDA-IV patients HbF levels of up to 37% of total hemoglobin 
have been reported20, even the most highly expressed embryonic globin in adult Klf1wt/
Nan mice, mz, contributes only 0.3% to the total amount of α-like globins. KLF1 activates 
expression of BCL11A14, 40 and LRF41, two transcriptional repressors directly involved in 
hemoglobin switching42, 43. RT-qPCR analysis of BCL11A and LRF expression indicates 
that reduced expression of these two factors contributes to the sustained expression 
of the embryonic/fetal genes in Klf1wt/nan erythroid cells (Supplementary Figure 2). We 
note that expression of BCL1A is also significantly reduced in Klf1wt/ko cells with little 
effect on expression of the embryonic/fetal genes36. Mechanistically, this suggests that 
the repressor proteins are expressed well above the critical threshold level in mice, and 
a reduction to 40-60% of normal expression would still be sufficient for quantitative 
silencing of the embryonic/fetal genes.
The impaired proliferation of E12.5 fetal liver-derived Klf1wt/Nan erythroblasts was 
initially surprising because lack of KLF1 increased proliferation, likely due to impaired 
spontaneous differentiation9. Whereas erythropoiesis in Klf1ko/ko mice is severely affected 
during terminal differentiation, erythropoiesis in Klf1wt/nan mice is much less affected 
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with respect to terminal differentiation. Presence of KLF1Nan not only results in reduced 
expression of KLF1 target genes, but also induces expression of genes not normally 
regulated by KLF126, 27, 44. The combined effects of deregulation of canonical KLF1 target 
genes and ectopic gene expression likely underlie the observed lineage commitment 
and impaired proliferation and differentiation of Klf1wt/nan erythroblast cultures. 
Defective growth of erythroid progenitor cultures derived from a CDA-IV patient has 
been reported45, 46, indicating that impaired proliferation of erythroid progenitors is 
another hallmark that CDA-IV patients and Klf1wt/Nan mice have in common. In contrast, 
adult Klf1wt/nan mice expressed mainly adult-type globin genes, as opposed to adult 
CDA-IV patients who maintain expression of embryonic and fetal globins at substantial 
levels20-22, 45. 
Importantly, the dominant effect of KLF1Nan is illustrated by comparison with Klf1wt/ko 
mice which do not display deregulated expression of mouse embryonic globins in E14.5 
yolk sac and fetal liver and adult bone morrow36 (Supplementary Figure 3). We found 
that the effects of KLF1Nan on developmental regulation of globin expression are very 
consistent, but surprisingly subtle. KLF1Nan affects the dynamics of progression from 
primitive to definitive erythropoiesis during mouse development. Compared to control 
embryos, definitive erythrocytes emerge at a later stage as the dominant cell type in the 
circulation of Klf1wt/Nan embryos. We propose that this is at least in part due to the reduced 
expansion and differentiation capacity of the fetal liver progenitors, since cultured 
Klf1wt/Nan E12.5 fetal liver cells display growth and differentiation defects. Consistent 
with impaired erythroid differentiation, we observed aberrant expression of erythroid 
flow cytometry markers (CD71, Ter119, CD9). Furthermore, we found misexpression of 
myeloid markers, in particular the megakaryocyte marker CD41, indicating that Klf1wt/Nan 
erythroid progenitors display lineage infidelity. This is akin to the previously reported 
aberrantly activated megakaryocyte program in Klf1ko/ko erythroid cells39, 47.
Collectively, our data support the notion that KLF1CDA and KLF1Nan present with similar 
but also variant-specific phenotypes. Thus, our study further highlights the need to 
investigate the effects of individual KLF1 variants in detail1. The recently developed 
human adult erythroid progenitor cell lines HUDEP-248 and BEL-A49 could be combined 
with CRISPR-mediated homology-directed recombination50 to investigate the impact of 
individual human KLF1 variants on the molecular control of erythropoiesis, with a view 
to increase understanding of the broad spectrum of human red blood cell disorders 
caused by KLF1 variants1.
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Supplementary material and methods
Supplementary Table 1.
  Klf1 wt/wt (n=4) stdev Klf1 wt/Nan (n=4) stdev fold-change
mey 0.0001 0.00003 0.0032 0.00232 54.06
mβh1 0.0000 0.00002 0.0006 0.00048 13.39
mβ 0.9999 0.00002 0.9961 0.00278 1.00
mz 0.0000 0.00000 0.0010 0.00207 307.84
mα 1.0000 0.00000 0.9990 0.00207 1.00
he 0.0000 0.00000 0.0007 0.00068 165.86
hγ 0.0049 0.00239 0.0494 0.01064 10.05
hβ 0.9951 0.00239 0.9498 0.01122 0.95
Globin expression in cultured E12.5 fetal liver cells (Day 6 of culture) was assessed by RT-qPCR. 
Globin expression was calculated as fraction of total mβ-like, mα-like or hβ-like globin. Fold-change is 





Supplementary Figure 1. Visual abstract summarizing the main observations reported in this paper 
 
 
Supplementary Figure 2. Expression of BCL11A and LRF in 
erythroid tissues of control and Klf1wt/Nan embryos 
Expression of BCL11A and LRF in fetal livers (E13.5 and E16.5) and 
adult bone marrow was determined by RT-qPCR. Expression of 
P112 was used as a reference to normalize the data; the average 
expression level in the control samples was set to 1. Asterisks 
indicate p-values<0.05; error bars indicate standard deviations. 
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Supplementary Figure 2. Expression of BCL11A 
and LRF inerythroid tissues of control and Klf1wt/Nan 
embryos. Expression of BCL11A and LRF in fetal 
livers (E13.5 and E16.5) and adult bone marrow 
was determined by RT-qPCR. Expression of P112 
was used as a reference to normalize the data; the 
average expression level in the control samples 
was set to 1. Asterisks indicate p-values<0.05; error 




Supplementary Figure 3. Expression of mouse embryonic globins in erythroid tissues of Klf1wt/ko and Klf1wt/Nan embryos 
Expression of mouse embryonic globins in E14.5 yolk sac and fetal liver and adult bone marrow was determined by 
RT-qPCR. The average expression level in samples from control littermates (indicated by the red line) was set to 1. 
Asterisks indicate p-values<0.05 between Klf1wt/ko and Klf1wt/Nan samples; error bars indicate standard deviations. Note 




Mice were maintained by breeding Klf1wt/Nan::HBB males with C57BL/6 females. Genotyping was performed by PCR using 
DNA isolated from toe biopsies. For Klf1Nan genotyping, the PCR product was digested with DpnII 2.  
Primers used for genotyping 




Approximately 340 bp PCR product for the wildtype Klf1 allele, and 240 + 100 bp for the Klf1Nan allele after DpnII 
digestion 2. 
PAC8.1 human HBB locus single copy transgene 3 
Fw: GCTGCTGTTATGACCACTAGAGGG 
Rv: AGACAGGGAAGGAGGTGTGG 
PCR product 500 bp. 
PCR conditions: 3 min 94°C, 28 cycles [30 sec 94°C, 30 sec 56°C, 30 sec 72°C], 2 min 72°C. 
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Supplementary methods
Animals
Mice were maintained by breeding Klf1wt/Nan::HBB males with C57BL/6 females. Genotyping 
was performed by PCR using DNA isolated from toe biopsies. For Klf1Nan genotyping, the 
PCR product was digested with DpnII 2.
Primers used for genotyping




Approximately 340 bp PCR product for the wildtype Klf1 allele, and 240 + 100 bp for the 
Klf1Nan allele after DpnII digestion 2.
PAC8.1 human HBB locus single copy transgene 3
Fw: GCTGCTGTTATGACCACTAGAGGG
Rv: AGACAGGGAAGGAGGTGTGG
PCR product 500 bp.
PCR conditions: 3 min 94°C, 28 cycles [30 sec 94°C, 30 sec 56°C, 30 sec 72°C], 2 min 72°C.
For timed pregnancies, Klf1wt/Nan::HBB males were mated with C57BL/6 and C57BL/6HBB 
females. The day of vaginal plug discovery was considered E0.5. Embryos were collected 
between E11.5 and E16.5; head DNA was used for genotyping. Adult mice were analyzed 
at >18 weeks of age.
RT-qPCR
To synthesize cDNA, 2 μg of total RNA was used together with oligo dT, RNase OUT, and 
SuperScript reverse transcriptase II (all Thermo Fischer Scientific) in a total volume of 20 
μl for 1 hour at 42°C. 0.2 μl of cDNA was used for amplification by RT-qPCR.
Primers were designed using Primer-BLAST, available through the NCBI web site at 
https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome. 
PCR product size was set to ‘Maximum 150 bp’. To avoid inter-globin and inter-species 
cross-specificity, the primer pair specificity checking parameters were set to ‘Enable 
search for primer pairs specific to the intended PCR template’ and ‘Database-Genomes 
for selected organisms (primary reference assembly only)-Homo sapiens, Mus musculus’. 
Exon/intron selection was set to ‘Primer pair must be separated by at least one intron 
on the corresponding genomic DNA’ and Intron length range ‘Minimum 100 bp’. All other 




Gene  globin encoded  Primer pair   PCR product (bp)
Hba-x  mz   CCGGTCAACTTCAAGCTCCT 103
     TGAACTTGTCCCAGGCTTCG
Hba-a1 mα1    GCTGAAGCCCTGGAAAGGAT 82
     CAGAGCCGTGGCTTACATCA
Hba-a2 mα2    Identical to Hba-a1
Hbb-y mey    TTGGCTAGTCACTTCGGCAAT 145
     GCATAGCGGACACACAGGAT
Hbb-bh1 mβh1    TGGGCTTGGGGGTTAAGAAC 118
     AACATGTTGCCCAGGAGCTT
Hbb-b1 mβmajor    GCTGCATGTGGATCCTGAGA 112
     CTTCTGGAAGGCAGCCTGTG
Hbb-b2 mβminor    Identical to Hbb-b1
Human globins
Gene  globin encoded  Primer pair   PCR product (bp)
HBE  he   CCCTGGCCCATAAGTACCAC 105
     TTTCTCTCAAGGCCAAGCCC
HBG1  hAγ   GGTGACCGTTTTGGCAATCC 106
     GTATCTGGAGGACAGGGCAC
HBG2  hGγ   Identical to HBG1
HBB  hβ   GCCCTGGCCCACAAGTATC 109
     GCCCTTCATAATATCCCCCAGTT
Mouse transcription factors
Gene  factor encoded  Primer pair   PCR product (bp)
Bcl11a  BCL11A   CGTGTGCAGACCGAGGAGAGG 129
     GCATCCAGGTCACGCCAGAGG
Zbtb7a  LRF   AGAAGGTGATTCAGGGTGCC 112
     AGCTTGTCCTGTCTGGTGAAT
Mouse cell cycle regulators
Gene  factor encoded  Primer pair   PCR product (bp)
E2f2  E2F2   CTGAATTCCGGACCCCCAAG 101
     CGACGTGTCATAGCGTGTCT
E2f4  E2F4   GCTTGGCCTACGTGACTCAT 100
     ATGGGCACCTCTAGACTGGT
Cdkn1a  P21   GAATTGGAGTCAGGCGCAGA 89
     GAACAGGTCGGACATCACCA
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Cdkn2c  P18   AATGGATTTGGGAGAACTGCG 70
     GGAGAAGCCTCCTGGCAATC
Mouse reference gene
Gene  protein encoded  Primer pair   PCR product (bp)
Psmd1  P112   AATGTTCCAGCGATGTCTCG 150
     GACATGCAGAGTTTGAGGCTG
Quantitative PCR
PCR amplification was performed on a CFX96 Touch Real-Time PCR Detection System 
(Bio-Rad, Hercules, CA) using Platinum Taq DNA polymerase (Invitrogen). PCR conditions 
were 3 min 95°C, 40 cycles [30 sec 95°C, 25 sec 60°C, 15 sec 72°C], 5 sec 60°C, 5 min 
95°C. Specific PCR product accumulation was monitored by SYBR Green dye fluorescence 
(Sigma-Aldrich, Saint Louis, MO). Using dilution series of yolk sac and fetal liver cDNAs, 
we found that the linear dynamic range of all globin primer pairs exceeded 256-fold 
dilution of the initial cDNA concentration. Dissociation curves were used to assess the 
homogeneity of PCR products. In addition, PCR product sizes were checked by agarose gel 
electrophoresis. To obtain expression values, Ct values were transformed by computing 
2-Ct. Total mα-like (mz+mα), mβ-like (mey+mβh1+mβ) and hβ-like globins (he+hγ+hβ) 
expression was used to calculate the contribution of individual globins to the total 
for each globin in each sample, e.g. mz/(mz+mα) and mα/(mz+mα) for mα-like globins. 
These fractional values were used to calculate the average and standard deviation for 
all samples belonging to the same group (e.g. Klf1wt/Nan E12.5 fetal liver). Analysis of RNA-
seq data revealed that, compared to commonly used reference genes such as GAPDH and 
ACTB, expression of PSMD1 (encoding P112, a proteasome 26S subunit) was relatively 
stable in primary human erythroblasts cultured under self-renewal or differentiation 
conditions (Heshusius et al, manuscript in preparation). We therefore used Psmd1 as a 
reference gene to normalize expression levels of the Bcl11a and Zbtb7a genes.
Culture of mouse erythroid progenitors
E12.5 fetal livers were disrupted and single cell suspensions were seeded into StemPro 
medium (Thermo Fisher Scientific, Waltham, MA) supplemented with 1 U/ml human 
recombinant erythropoietin (EPO; Cilag, Schaffhausen, CH), 10 ng/ml murine recombinant 
stem cell factor (SCF; Supernatant of cells harbouring an expression construct) and 10-6 
M dexamethasone (Dex; Sigma-Aldrich, Saint Louis, MO) 4. The cultures of erythroid 
progenitors were subjected to daily partial medium changes and addition of fresh factors. 
Cell numbers and size distributions were determined daily, using an electronic cell 
counter (CASY; Roche, Basel, CH). Cell density was kept between 0.5-2.0x106 cells/ml. To 
differentiate erythroid progenitors, cells were washed twice in phosphate-buffered saline 
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(PBS) and seeded at 1.5x106 cells/ml in differentiation medium: StemPro supplemented 
with 10 U/ml EPO and 1 mg/ml iron-saturated human transferrin (Sigma-Aldrich). Cells 
were maintained at densities of 2-4x106 cells/ml. 
Flow cytometry analysis
Single-cell suspensions of peripheral blood samples were washed twice with PBS and 
resuspended in FACS buffer (PBS containing 1% (w/v) bovine serum albumin, 2 mM 
EDTA). Approximately 106 cells were incubated for 30 minutes at room temperature 
with CD71-BV421 (562716, dilution 1:400; BD Biosciences, San Jose, CA), CD9-PE 
(12-0019-81, dilution 1:300; Thermo Fischer Scientific) and Ter119-APC (17-5921-
82, dilution 1:200; Thermo Fischer Scientific) antibodies in a final volume of 100 μl. 
Antibodies were diluted in FACS buffer. The cells were washed, and living cells were 
distinguished negatively by live/dead Aqua staining (L34965; dilution 1:400; Thermo 
Fischer Scientific). Cultured cells were washed with PBS and incubated in for 30 minutes 
at 4 ºC in FACS-buffer with CD71-APC (130-091-727, Miltenyi Bergisch Gladbach DE, 
dilution: 1:200), Ter119-BV450 (48-5921-82 Thermo Fischer Scientific, dilution 1:200), 
Ly6G-PE (RB6-8C5, Thermo Fischer Scientific, dilution 1:100), F4/80-FITC (11-4801-
85, BD Biosciences, dilution 1:200), CD11b-AF488 (101217, Biolegend San Diego CA, 
dilution 1:100), CD41PE (12-0411-82, Thermo Fischer Scientific, dilution: 1:100).Data 
were acquired on a Fortessa instrument (BD Biosciences), and analyzed with FlowJo 
software v10 (Tree Star, Ashland, OR).
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Chapter 6 - General Discussion
The aim of this thesis was to advance knowledge on the regulation of fetal hemoglobin 
genes and identify novel candidate modifiers of its expression. To achieve this, we 
improved our in vitro cell culture of human erythroblasts and used this cell culture 
model to investigate genetic determinants and environmental factors that affect HbF 
expression. Here I will discuss how the data generated in this thesis can be integrated 
with current knowledge to extend the models of developmental gene expression during 
erythropoiesis and what the implications are for development of novel HbF inducing 
agents.
Cultured cells express higher levels of fetal hemoglobin along 
with genes associated with the integrated stress response.
We generated transcriptome profiles that cover the entire course of terminal 
differentiation leading up to and beyond enucleation. Comparison of the transcriptome 
of the cultured cells and of ex vivo cells at a similar stage showed a high correspondence 
for most detectable transcripts (chapter 2). Although the transcriptome of the ex vivo 
erythroblasts were derived from a previous publication1 the transcriptomes matched 
well with the exception of the HBG genes that show a higher expression in cultured cells. 
Closer examination of the transcriptome of the cultured cells, in comparison to their ex 
vivo counterparts, provides an opportunity to determine which components of the culture 
setup affect HbF expression in vitro.
Next to increased expression of the HBG genes, nearly 2,000 of the 13,000 detectable 
transcripts were expressed at least four-fold higher or lower in cultured compared to 
ex vivo cells. Referenced against the Reactome database, that catalogs information on 
molecular pathways2, the top 5 enriched pathways expressed higher cultured cells 
included genes associated with cellular senescence and cellular response to stress 
(table 1), which could mean that there is indeed higher oxidative stress under the cell 
culture conditions used. 
Table 1. Enriched term in genes expressed in cultured erythroblasts 
Reactome term Overlap P-val P-adj
Cellular Senescence_Homo sapiens_R-HSA-2559583 57/161 8.8E-19 1.35E-15
Metabolism of proteins_Homo sapiens_R-HSA-392499 194/1074 7.21E-18 5.51E-15
HDACs deacetylate histones_Homo sapiens_R-HSA-3214815 32/60 2.6E-17 1.32E-14
Cellular responses to stress_Homo sapiens_R-HSA-2262752 89/367 3.27E-16 1.25E-13
DNA Damage/Telomere Stress Induced Senescence_Homo 
sapiens_R-HSA-2559586
30/59 1.45E-15 4.44E-13





The induction of HbF in response to stress has been described as part of the mechanisms 
of HbF inducing agents like hydroxyurea.3 This would fit with the higher levels of HbF 
observed in erythroid cultures resulting from increased oxidative stress under prolonged 
SCF and EPO stimulation or from extensive expansion of progenitors in the culture 
system.4,5 
Signals from oxidative stress can be relayed to drive transcription by the cellular 
stress response via p38 mitogen activated kinase signaling and the integrated stress 
response (ISR). These pathways converge on a set of activating transcription factors, 
including ATF2-4, CHOP and MYC, that can in turn induce higher levels of HbF.6,7 With 
the exception of ATF2 these factors are expressed between 16- and 32-fold higher in 
cultured cells (Fig. 1A). Also, the targets of these factors are overrepresented in the 
genes that are expressed higher in vitro; of the 351 detected CHOP and ATF4 targets8 
in our transcriptome dataset, 101 genes showed over four-fold higher expression in 
cultured cells (Fig. 1B p= 4.0e-8). Similarly, high expression of nearly a third of the known 
ATF4 targets (without CHOP) could indicate increased activity of the ISR pathway and 
would help explain increased HbF levels in cultured cells. Although overrepresentation 
of stress associated pathways and some of their core regulators implicates the ISR 
pathway for regulation of HbF in cultured cells, to which extent activation is triggered 
by higher ROS in cultured cells remains to be investigated. 
Figure 1. Expression of genes associated with ATF4 and CHOP. (A) mRNA expression for transcription 
factors central to integrated stress response (n=3-4 bar plot showing mean ±sd.) (B) Comparison of 
transcript levels for ATF4 and CHOP target in day cRBC and Ex-vivo cells. 
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ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA 
expression_Homo sapiens_R-HSA-427389 
25/43 5.25E-15 1.34E-12 
The induction of HbF in response to stress has been described as part of the 
mechanisms of HbF inducing agents like hydroxyurea.3 This would fit with the higher 
levels of HbF observed in erythroid cultures resulting from increased oxidative stress 
under prolonged SCF and EPO stimulation or from extensive expansion of progenitors 
in the culture system.4,5  
Signals from oxidative stress can be relayed to drive transcription by the cellular stress 
response via p38 mitogen activated kinase signaling and the integrated stress 
response (ISR). These pathways converge on a set of activating transcription factors, 
including ATF2-4, CHOP and MYC, that can in turn induce higher levels of HbF.6,7 With 
the exception of ATF2 these factors are expressed between 16- and 32-fold higher in 
cultured cells (Fig. 1A).  Also, the targets of these factors are overrepresented in the 
genes that are expressed higher in vitro; of the 351 detected CHOP and ATF4 targets8 
in our transcriptome dataset, 101 genes showed over four-fold higher expression in 
cultured cells (Fig. 1B p= 4.0e-8). Similarly, high expression of nearly a third of the 
known ATF4 targets (without CHOP) could indicate increased activity of the ISR 
pathway and would help explain increased HBF levels in cultured cells. Although 
overrepresentation of stress associated pathways and some of their core regulators 
implicates the ISR pathway for regulation of HBF in cultured cells, to which extent 
activation is triggered by higher ROS in cultured cells remains to be investigated.  
 
 
Figure 1 Expression of genes associated with ATF4 and CHOP (A) mRNA expression for transcription factors central to 
inte rated stress resp nse (n=3-4 bar pl t showing mean ±sd.) (B) Comparison of transcript levels r ATF4 and CHOP 
target in day cRBC and Ex-vivo cells.     
 
To offset the detrimental effects of high ROS levels, cells produce antioxidizing 
enzymes like, heme oxygenase-1 (HO-1).9 NRF2, encoded by NFE2L2, and KEAP1 are 
two central transcription factors involved in the cellular response to ROS production 
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To offset the detrimental effects of high ROS levels, cells produce antioxidizing enzymes 
like, heme oxygenase-1 (HO-1).9 NRF2, encoded by NFE2L2, and KEAP1 are two central 
transcription factors involved in the cellular response to ROS production (reviewed 
by Itoh et al.10). KEAP1 binds NRF2 and targets it for degradation thereby inhibiting 
activation of NRF2 target genes. Interestingly, NRF2, a master regulator of antioxidant 
expression, is expressed at levels comparable to ex vivo cells, but the inhibitory protein is 
expressed to much higher levels in cultured cells. This would suggest that at transcript 
level, the cultured cells are not showing a canonical response to offset increased ROS 
levels, which could mean that the ISR is activated by a different source of stress.
Three-fold higher expression of ATF6B in cultured compared to ex vivo cells could 
serve as an indication that the unfolded protein response (UPR) and ER stress are 
driving activation of stress pathways. Unlike other members of the ATF family, ATF6B 
is specifically activated by ER stress and UPR.11 We did not explicitly measure these 
potential sources, but with the large amount of hemoglobin that needs to be formed 
during erythroid differentiation it is conceivable that misfolded proteins arise. Implicitly, 
the HPLC analysis picking up HbH, a tetramer of beta-globin chains, shows there is 
incorrect globin pairing in cultured cells (chapter 2). Although these molecules can 
precipitate to form Heinz bodies a it does not confer misfolded Hb molecules.
Another source of cellular stress that would specifically relate to our culture setup is 
triggering of the UPR / ER stress branch of the ISR in reaction to lipid imbalances in the 
medium 12. This mode of activation has been described to occur in hepatocytes 13 and 
would fit with the observation from our own preliminary metabolomics experiments 
that show lipid precursors are rapidly depleted from Cellquin at the start of culture.
Notably, besides HBG and genes associated with the ISR, upregulated genes in cultured 
cells included core regulators of erythropoiesis and hemoglobin switching KLF1, GATA1 
and GATA2. While higher expression of the core regulators could help explain higher 
expression of many of the other genes, a notion that is supported by enrichment of KLF1 
and GATA1 ChIP targets in the set of 2000 genes. This observation would be at odds 
with increased HbF expression: LRF and BCL11A also showed increased expression, to a 
maximum of 2-fold higher compared to ex vivo cells. 
At face value the observation on the increased expression of the core regulators and 
the observation on increased activity of ATF4 could indicate that the HBF inducing 
effect of stress-associated pathways overrides that of the core regulators of hemoglobin 
switching in erythroid cultures. 
Contradictory to this notion, recent work on the role of the HRI-EIF2a-ATF4 signaling 
axis cells suggests that it activates BCL11A to repress HbF expression 14. In this study 
increased ATF4 is proposed to bind the +55 enhancer of BCL11A to provide direct 
regulation through chromatin looping to the promoter of BCL11A. The effect might be 
system specific as it could not be detected in mice. 
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Higher levels of ATF4 results from increased translation due to higher activity of 
heme-regulated EI2-kinase (HRI), which is the dominant EIF2 kinase in erythroid cells 
15,16. Unlike its downstream target HRI was not expressed at higher levels in our cultured 
cells. Combined with the discrepancy for ATF4 and the inability to detect its effect in 
mice this raises the question to which extent the repression of HbF by the HRI-EIF2a-
ATF4 signaling axis is a biologically relevant mechanism or only present in specific 
culture conditions. Gene expression profiles on their own provide limited ground to 
discuss this question. Therefore, our observations on ATF4 and the globin regulators 
would have to be corroborated by protein measurements. 
Even though combined RNA sequencing with proteomics approaches generally find 
mRNA abundance a decent predictor of protein levels in steady state conditions, the 
correlation between mRNA and protein become less apparent in dynamic processes, like 
the state transitions of differentiation (reviewed in Liu et al17). The temporal changes 
in mRNA and protein can start to diverge between up and down regulated genes due 
to different modes of regulation in the differentiation process. For example, higher 
activity of ATF4 would have to be confirmed by protein measurements, because altered 
translation efficiency resulting from EIF2 phosphorylation is central to the regulation 
of its protein levels 6. Similarly, differences in KLF1 and GATA1 between ex vivo and 
cultured cells at transcript level might not reflect differences in protein levels, since 
a disconnect between the two measurements for these transcription factors was 
suggested in preliminary work that combines transcriptome and proteome analysis 
during erythroid differentiation 18. Taking into account that both KLF1 (chapter 4) and 
GATA1 can have dose dependent effects on gene regulation the necessity to confirm the 
observed differences at protein level becomes even more apparent 19,20. 
Collectively, the extended characterization of the Cellquin based culture setup suggests 
a role for stress associated pathway in inducing HbF expression. While we cannot rule 
out that this results from increased ROS levels in cultured cells, activation of the stress 
response through the unfolded protein response and ER-stress would be a better fit with 
the observations at transcript level. 
In addition to this mechanistic insight, this culture system facilitates the analysis of 
human erythroid progenitor cells by reducing the cost of the culture medium, providing 
high yields, and robustly recapitulating erythroid characteristics. At their current scale 
clinical safety tests have become feasible, which brings their use for transfusion of beta-
hemoglobinopathy patients or other therapeutic applications a step closer.
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Environmental signaling can repress fetal hemoglobin 
expression
Although our culture system lacks the 3D-organisation that makes up the bone marrow 
niche, its components constitute an environment where a mix of signals results in cells 
functionally equivalent to ex vivo cells. Most of the success with generating cultured 
erythroid cells comes from exploiting the general signaling cascades that initiate from 
EPO and SCF signaling.21 While in vivo erythropoiesis requires membrane-bound SCF for 
erythroid expansion, supplying the soluble form along with EPO and dexamethasone 
is sufficient for robust expansion of progenitor cells in vitro.22,23 The cell intrinsic 
capacity for erythropoiesis in response to a limited set of signals makes it difficult to 
delineate the role of the erythroid niche, for which erythroid progenitors and central 
macrophages are considered the main constituents. Despite the identification of various 
functional interactions between these cell types, conflicting reports on the requirement 
of these interactions make it difficult to determine their exact contribution to steady 
state erythropoiesis. A major contribution of niche interactions appears to come from 
providing support in periods of stress erythropoiesis [reviewed by 24,25]. 
Addition of dexamethasone to the Cellquin culture medium induces signaling 
cascades that are normally active during stress-erythropoiesis.22,26 In addition, previous 
characterization of the culture system using PBMCs has shown that the monocyte 
fraction (CD14+) stimulates erythroid outgrowth and obtains a central macrophage 
like phenotype in response to dexamethasone.27,28 In follow up to these previous 
observations we employed the Cellquin culture system to investigate the role of cell-
cell interactions in regulation of HbF expression (chapter 3) and found that cultures 
started from peripheral blood mononuclear cells (PBMCs) express lower levels of HbF 
when compared to those started from hematopoietic stem- and progenitor cells (HSPCs; 
CD34+ fraction) alone. The HSPC derived cultures showed an increased proportion of 
cells that express both adult and fetal hemoglobin. Lack of this same effect in transwell 
cultures shows that the repression of HbF depends on cell-cell proximity and does 
not result from increased yield or selective outgrowth of HbA-only cells. Similar 
to our observation a recent publication that combined transcriptome and proteome 
analysis on the populations proposed that differences between the two result from 
transcriptional control at the level of the β-globin locus.29 The lack of differences in 
the transcriptomes of the HbA and HbF populations, along with the repressive effect 
on HbF being most pronounced in co-cultures with the CD34+CD36- fraction suggests 
that potential changes to transcription influencing HbF expression occur in the earlier 
stages of erythroid specification. 
Aside from a dependence on cell-cell proximity we did not find the mechanism through 
which HbF repression in PBMC cultures occurs. Following an argumentation where 
repression would result from an active process and combining this with a potential HbF 
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inducing effect of ROS or lipid imbalance by activating the integrated stress response 
pathway, one could argue that CD14+ cells repress HbF expression by shaping the in 
vitro environment. For example, CD14+ derived macrophages could scavenge access ROS 
molecules, provide lipid intermediates or balance access lipids for the early progenitors, 
which in turn reduces activation of the stress-response pathways. This would fit with an 
assumed role for the erythroid niche supporting stress erythropoiesis, by allowing cells 
to rapidly expand without triggering apoptosis as a result of disbalanced pro-survival 
and pro-apoptotic signals.30 
Outside of a balancing effect of CD14+ derived central macrophages on the 
extracellular environment culture, it is interesting to speculate that cell-cell contact or 
proximity triggers a signaling cascade that actively represses HbF expression. 
The importance of interaction between erythroid progenitors and central macrophages 
has been proposed from observations on embryonic lethality in mice lacking the 
erythroblast macrophage protein (Emp).31 An inhibitory effect on HbF expression from 
active environmental signaling has been proposed from the observation of a fetal-to-
adult globin switch of human erythroid precursors upon injection in mice 33. A possible 
mechanism to relay such an active signaling event in human cultured cells would be 
locus priming, which has already been established during hematopoiesis with the “GATA-
switch”. One line of reasoning follows the premise that this switch results from gradual 
replacement of GATA2, required for genesis and early progenitor gene expression, by 
GATA1 at specific loci, which in turn drives lineage specific gene expression.34–36 
While another line of reasoning posits spatiotemporal regulation of Gata factor levels 
rather than an Gata identity switch as driving force for functional erythropoiesis.37 This 
spatiotemporal nature would fit with the observation that the HbF repression from the 
CD14+ fraction is most pronounced in co-cultures with early stage progenitors. 
More specifically, at the hemoglobin locus the GATA factor and its co-factor FOG1 
have been suggested to facilitate the proximity between the LCR and adult globin 
promoter region to regulate adult stage globin expression 38,39. These same complexes 
have been shown to recruit NuRD-complexes to the distal promoter regions of the HBG 
genes providing a mode through which it could convey direct repression of the fetal 
stage globin genes.40,41 
Future work, should first determine if the repressive effect indeed results from an 
active interaction between the CD14+ central macrophage like cells and the erythroid 
progenitors. If this can be established it would be interesting to see which signaling 
pathways initiate from the interaction and test whether it is the exchange of GATA 
factors or another form of priming that leads to increased HbF expression in the progeny 
of the CD34+ cells. This would be a first account of repressive niche effect, that shares a 
similarity to the fetal-to-adult globin switch that has been reported in the transfusion 
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of human erythroid progenitors in mice.33 The identification of such a signaling cascade 
could provide novel means to interfere with previously described modes of HbF regulation. 
Genomic variants affect fetal hemoglobin expression through 
altered KLF1 availability
Whereas it is not yet clear how signals from the environment (macrophage interactions) 
or generated intracellularly (activation of p38 and the ISR) control globin switching, it is 
clear that the transcription factor KLF1 has a central role in control of globin expression. 
Our application of the culture model in combination with samples from the Maltese 
hereditary persistence of fetal hemoglobin (HPFH) cohort allowed the examination of the 
KLF1 p.K288X variant on inducing HbF expression. While the individuals in this cohort 
share this haploinsufficiency inducing variant, their HbF levels show a wide variation.20 
Despite an overall increase of HbF levels in the cell culture the residual variation in 
HbF expression, found in vivo, was retained between individuals from the same family 
(chapter 4). Exploiting this characteristic, we assessed chromatin accessibility along with 
the transcriptome and promoter analysis in the cohort. Although the overall chromatin, 
including the HBG promoter had a more open structure in KLF1 haploinsufficient 
individuals our findings suggest that the main driver for incomplete penetrance of the 
HbF phenotype is the rs3817621 SNP, which reduces the expression from the wildtype 
KLF1 promoter. We proposed that the HBG genes might be particularly susceptible to 
the resultant compound heterozygosity, because both repression of fetal stage globin 
and activation of adult stage globin could be affected by the microvariations in KLF1 
levels. 
An important consideration to these observations is that although the hypothesis 
holds for the cultured samples, in vivo the observation only generalized to the individuals 
from the original pedigree tested in 2010.20 The individual with the SNP from the other 
pedigree was grouped as a “high” HbF donor in vitro, but it had the lowest levels of 
the HPFH cases in vivo. Interestingly, also the non HPFH relatives from this pedigree 
showed a higher induction of HbF over its in vivo levels; about 20-fold compared to 
~5-fold in the other pedigree. From this observation one can speculate that there is 
yet an undetermined genetic factor that either renders individuals from this pedigree 
particularly susceptible to HbF inducing conditions in the culture setup, or results in 
lower HbF in vivo. Further testing of relatives, both with and without HPFH can help to 
determine this. 
Whereas, the compound heterozygosity with the KLF1 p.K288X variant shows the effect 
of KLF1 levels on the regulation of HbF expression, our analysis of Nan-mice, carrying the 
Klf1 p.E339D variant, shows how altered DNA binding can affect HbF (chapter 5). Similar 
to the human KLF1 p.E325K variant, that causes congenital dyserythropoietic anemia 
(CDA type IV), the Nan variant results in retained embryonic/ fetal globin expression 
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beyond the stage of primitive erythropoiesis and causes erythropoietic defects. The Nan 
and the CDA variant result from different mutations affecting an orthologous amino 
acid in the middle zinc-finger of KLF1.42,43 It is conceivable that the lack of high levels of 
HbF expression in Nan-mice results from a variant specific effect that differs between a 
KLF1 protein with a lysine (CDA) and an aspartic-acid (Nan) in the DNA binding α-helix. 
Particularly, since recent work that recreated the E > K mutation in a mouse cell line 
suggests that the both CDA and Nan-variants share altered binding to the β-globin 
promoter, yet manifest different binding affinities for other target genes.44,45 
Regardless if lower local transcription factor availability result from variants that 
directly alter binding affinity or those that affect availability through transcriptional 
regulation. the combinatorial effects of different variants on the penetrance of 
a trait underlines the importance of additional genetic screening when it comes to 
understanding disease mechanisms. Particularly, in the event of haploinsufficiency 
of transcription factors that serve as upstream nodes in regulatory networks.46 While 
regulation of HbF by its core regulators can certainly be described in terms of a 
regulatory network, formally the simultaneous interplay of the ensemble of regulators 
and the 3-dimenstional chromatin structure at the locus has not been combined in 
a gene regulatory network model (GRN). Although this type of approach might not 
yield fundamentally new insights, it would provide a means to predict dose effects 
of transcription factor levels, like we observed here for compound heterozygosity for 
KLF1 or the proposed differences in binding affinity for two variants of Klf1. A better 
understanding of these dose effects would facilitate testing and development of 
combinatorial therapies that induce HbF expression.
Concluding remarks
In the general introduction I described how our knowledge on molecular biology in 
general and the hemoglobin switch in particular co-evolved with the tools that 
progressively allowed more comprehensive hypotheses on the nature of gene regulation 
to be formed. The strive to understand the mechanisms of hemoglobin switching was 
paired with a desire to control these mechanisms in order to design new treatments for 
β-hemoglobinopathies. 
A key insight at the basis of molecular biology was to view genetic material as a means 
to transfer information.47 From this premise genes could be reduced to the minimal unit 
required for transmission with the coding sequence, enhancers, distal control regions 
and higher organizational domains as main building blocks. For the hemoglobin genes 
this reductionist approach has resulted in a well-defined set of core regulators that are 
involved in their regulation. While this core set of regulators allows for a more directed 
approach in attempts to induce HbF expression it has also narrowed the search horizon; 
most efforts are directed at reversing direct repression by BCL11A. This leaves less 
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room for trying to understand the developmental interplay of the different regulators, 
which despite identification of many components is still incompletely understood. 
The chapters of this thesis underline how variable penetrance of HPFH in response 
to transcription factor microvariations, retained HbF expression as a result of reduced 
binding of KLF1 or lack of environmental cues serve as prime examples of research 
areas where treatment alternatives can still be found. 
With the advance of multi-omics and analysis at single cell level, molecular biology 
and computer sciences are increasingly intertwined. Sharing their conceptual origin in 
information theory, computational analysis of multi-omics serves as an important tool 
to address research question in the current period. Like the use of natural language 
programming to help with literature review in the introduction of this thesis, it is not 
that previous tools have been rendered obsolete or require less moderation. Rather, 
these novel tools focus on identifying patterns within larger bodies of information 
that when combined reveal essential structures of the process. This type of approach is 
facing problems with respect to moderation between signal and noise in more complex 
regulatory networks. Still, in combination with the mechanisms that have been defined 
to control hemoglobin switching at the level of the locus it can result in a more holistic 
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Hemoglobin molecules allow red blood cells to transport oxygen throughout our bodies. 
As a result of altered gene expression human hemoglobin molecules subsequently 
adopt embryonic, fetal and adult conformations. This phenomenon is often referred to as 
hemoglobin switching and is the main topic of this thesis. 
As I introduced in the general introduction, the high abundance of and easy access 
to red blood cells in the human body/blood has placed studies on the hemoglobin 
molecules in health and disease, at the forefront of developments in molecular 
biology. Hereditary anemias, such as β-thalassemia or sickle cell disease, were linked 
to genetic variations that result in malformed or mal expressed hemoglobin chains. 
The observation that expression of fetal hemoglobin ameliorated disease symptoms in 
the event of these anemias (also referred to as β-hemoglobinopathies) intensified the 
interest in the mechanisms of gene regulation during hemoglobin switching. 
The work in this thesis aims to advance our understanding of regulation of fetal 
hemoglobin expression by focusing on different aspects of erythropoiesis, the 
development from stem cell to red blood cell. Next to characterization of fetal 
hemoglobin expression in adult cultured cells, I describe the contribution of niche 
signaling and genomic background on the level of fetal hemoglobin in adults. I 
subsequently assessed the role of KLF1 in transcriptional regulation of hemoglobin 
switching in humans and in mice. Ultimately, this will contribute to development of 
treatments for β-hemoglobinopathies. 
In the second chapter I describe a culture system that allows generation of large 
number of red blood cells. My colleagues and I optimized a previously described system 
by developing a proprietary culture medium, Cellquin, that uses GMP-grade components 
and is compatible with use in G-Rex bioreactors. This allows the scale up required for 
generating sufficient numbers of cells required for transfusion. The resultant cells are 
functionally and morphologically comparable to ex-vivo red blood cells (i.e. freshly 
isolated red blood cells). When these cells prove robust in clinical trials, they could 
provide a basis for transfusion products for hemoglobinopathy patients. 
While matching most characteristics, cultured cells deviate from their ex-vivo 
counterparts by expressing higher levels of fetal hemoglobin. As a result, they provide 
an opportunity to study the effect of cell-cell interactions on the expression of fetal 
hemoglobin in this setup. Previously, transfusion experiments with human fetal globin 
expressing cells in mice provided proof of concept of induced switching to adult 
globin expression through signaling events. Similarly, we observed repression of fetal 
hemoglobin expression in adult cells that were grown in contact with the CD14+ 
monocyte fraction of PBMCs (i.e. peripheral blood mononuclear cells). In the presence of 
dexamethasone in the culture medium this cell fraction obtains characteristics similar to 
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the central macrophages, a component of the erythroid niche in vivo. Although we were 
unable to demonstrate the mechanism of the interaction beyond cell proximity, we did 
demonstrate temporal separation between the potential signal from the macrophage 
like fraction and repression of fetal hemoglobin expression.
Chapter four and five focus on the role of transcription factor KLF1. Aside from 
controlling expression of genes essential for erythropoiesis, KLF1 is part of a core 
network of transcriptional regulators that regulate expression of different globin genes. 
KLF1 activates adult hemoglobin expression by inducing interaction between the 
promoter and the locus control region. In addition, it controls the repression of fetal 
hemoglobin through activation of direct repressors, BCL11A and LRF. Conversely, lower 
KLF1 expression that results from gene expression from one instead of two alleles, 
ie. haploinsufficiency, causes higher levels of fetal hemoglobin. However, previous 
characterization of a Maltese pedigree with the same haploinsufficiency genomic 
variant reported different levels of fetal hemoglobin between individuals. Revisiting 
this donor cohort, we observed that the functional KLF1 allele contained an additional 
genomic variant in individuals with the highest fetal globin levels. The variant is located 
in the promoter of the gene and modulates KLF1 levels, which in turn affects globin 
expression.
Instead of focusing on the effect of genomic variants determining transcription 
factor levels, Chapter five explores effects of variants that result in altered binding 
characteristics of KLF1. We used the Nan-mouse model to characterize pre-natal 
hemoglobin switching in presence of the KLF1 p.E339D variant, which has an altered 
DNA binding domain. The location of the amino acid substitution in the mouse model 
is the same as the one found in human CDA-IV, a severe anemia that features high fetal 
hemoglobin expression in adults. Although human and mouse hemoglobin switching 
differ in timing and the exact chains that are expressed, we did observe a phenotypic 
similarity to CDA-IV with retained expression of embryonic and fetal hemoglobins. 
However, quantitatively the embryonic/fetal hemoglobin levels did not increase as high 
as they do in CDA-IV. In addition, KLF1nan cells displayed lineage infidelity during in vitro 
erythroid differentiation indicated by cells expressing pan-myeloid and megakaryocytic 
markers. In line with the findings presented in Chapter four the simultaneous 
phenotypic overlap and contrasts between transcription factor variants makes the 
point for extended characterization of transcription factor variants in human disease.
The general discussion in Chapter six continues from the main observations in 
this thesis. I explore the possible influence of the integrated stress response on fetal 
hemoglobin expression in cultured cells, highlights the potential for environmental 
signals to affect globin gene expression and supports the case for modeling of the 




Rode bloedcellen en hemoglobine
Rode bloedcellen zijn de meest voorkomende cellen in ons lichaam. Hemoglobine 
moleculen geven de cellen hun rode kleur en zorgen voor zuurstof transport door het 
lichaam. Hemoglobine moleculen bestaan uit twee paren van gelijke eiwitten, ook 
wel de globine ketens genoemd. ,De combinatie van deze gepaarde ketens verandert 
tijdens de ontwikkeling. Zo nemen hemoglobine moleculen achtereenvolgend een 
embryonale (embryonale globine ketens met foetale globine ketens), foetale en 
volwassen (respectievelijk een combinatie foetale met volwassen globine keten en twee 
paar volwassen globine ketens) conformatie aan. Aan de wisseling tussen verschillende 
conformaties wordt vaak gerefereert met de engelse term “Hemoglobin switching” en is 
het hoofdonderwerp van deze thesis.
Hemoglobine genen als model voor regulatie van genexpressie
In de algemene introductie leg ik uit hoe de enorme hoeveelheid rode bloedcellen in 
ons lichaam ervoor heeft gezorgd, dat veel van de eerste ontdekkingen in moleculaire 
biologie en geneeskunde zijn beschreven aan de hand van deze cellen. Zo werd al 
vroeg ontdekt dat een tekort aan rode bloedcellen, anemie, bijvoorbeeld als gevolg 
van β-thallasemie en sikkelcelziekte, konden worden toegeschreven aan een genetisch 
defect. En was de locatie op het DNA als eerst bekend voor de hemoglobine genen. De 
ontdekking dat foetale hemoglobine genen kunnen compenseren voor het ziektebeeld 
bij β-thalassemie en sikkelcelziekte, die resulteren van een defect aan de volwassen 
globine genen, zorgde ervoor dat interesse in de regulatie van deze genen toenam. 
Sindsdien zijn er verschillende mechanismes van de regulatie van globine genen ontdekt 
met als ultiem doel een behandeling te vinden voor anemie. 
Doel van het onderzoek
Het onderzoek in dit proefschrift draagt bij aan ontwikkelen van behandelingen 
voor erfelijke anemien door te kijken naar de regulatie van de globine genen tijdens 
erytropoëse, het proces waarin stamcellen differentiëren naar rode bloedcellen. Naast 
onderzoek aan de expressie van foetale globine genen in kweekcellen uit bloed afkomstig 
van volwassenen, hebben wij gekeken naar de rol die de cellulaire omgeving (niche) 
en genetische achtergrond spelen bij expressie van foetale globine genen. Daarnaast 
hebben we in meer detail gekeken naar de rol van KLF1, een belangrijk regulator eiwit 




Op dit moment worden patiënten met zware vormen van sikkelcelziekte of β-thalassemie 
herhaaldelijk behandeld met bloedtransfusies. Deze behandeling heeft als nadeel dat 
er na herhaaldelijke transfusies allo-immunisatie op kan treden, een afweerreactie van 
het immuunsysteem die geactiveerd wordt in reactie op de getransfuseeerde cellen. 
Hierdoor wordt hetsteeds lastiger om geschikt bloed te vinden voor dit soort patiënten. 
Transfusies met gepersonaliseerd kweekbloed zou in dit geval uitkomst kunnen bieden 
omdat we in het geval van lichaamseigen cellen geen immuunreactie verwachten. 
Tegen deze achtergrond optimaliseerden wij in het tweede hoofdstuk een methode die 
kan worden gebruikt om op grote schaal kweekbloed te maken en te testen in eerste 
klinische studies. Dit protocol werkt zonder dierlijke componenten en in kleine G-rex 
bioreactoren. Daarbij beschrijf ik hoe de experimentele rode bloedcellen in de meeste 
functionele en morfologische aspecten lijken oprode bloedcellen direct afkomstig uit 
bloed. In toekomstig onderzoek zal blijken of deze cellen robuust genoeg zijn om in 
transfusie te worden toegepast en daadwerkelijk zouden kunnen worden in gezet als 
behandeling tegen anemie.
Omgevingssignalen en regulatie van hemoglobine genen
Hoewel gekweekte bloedcellen lijken op de volwassen cellen waar ze van afstammen, 
vertonen ze ook afwijkende eigenschappen. Gekweekte cellen hebben bijvoorbeeld 
een hogere expressie van foetaal hemoglobine. 
In Hoofdstuk drie ga ik dieper in op het verschil in het aandeel foetaal hemoglobine 
cellen tussen ex vivo rode bloedcellen en geweekte cellen. 
Uit eerder onderzoek bleek dat menselijke foetale cellen direct volwassen hemoglobin 
tot expressie brachten op het moment dat deze cellen in muizen werden geïnjecteerd. 
Deze ogenschijnlijke flexibiliteit in hemoglobine expressie inspireerde ons om te te 
onderzoeken of wespecifieke omgevingssignalen konden aanwijzen die zorgen voor 
een verhoogd aandeel foetaal hemoglobine in volwassen cellen. Zo vonden wij dat de 
hoeveelheid foetaal hemoglobine in gekweekte cellen lager is wanneer stamcellen 
in direct contact met een ander type witte bloedcel worden opgekweekt. Hoewel het 
niet is gelukt om exact te beschrijven welk mechanisme er aan de basis lag van deze 
interactie, hebben we wel laten zien dat het specifiek lijkt te gaan om een interactie met 
de stamcel die word over gedragen door cel-cel contact. 
Effecten van KLF1 afwijkingen op hemoglobine genexpressie
In Hoofdstuk vier en vijf kijk ik naar de rol van de transcriptie factor KLF1 in de regulatie 
van hemoglobine genen . Deze transcriptie factor is essentieel voor verschillende 
processen binnen erytropoëse en is een van centrale actoren in regulatie van 
expressie van verschillende globine genen. KLF1 activeert het volwassen β-globine 
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gen door de promotor in nabijheid van de “locus control region” te brengen. Daarnaast 
representeert KLF1 expressie van BCL11A and LRF1, transcriptie factoren die op hun 
beurt foetaal γ-globine onderdrukken. Zo leiden lagere KLF1 niveaus, als gevolg van 
haplo-insufficiëntie (de expressie van een in plaats van twee allelen), tot hoger foetaal 
hemoglobine in volwassen cellen. Desondanks zijn er binnen een Maltese familie 
met dezelfde haploinsufficientie mutatie aan KLF1, verschillende niveaus van foetaal 
hemoglobine. Familieleden met de hoogste foetale hemoglobine expressen bleken ook 
een mutatie in het functionele allel van KLF1 te dragen, die het KLF1 niveau verder 
verlaagt. Deze bevinding onderstreept het belang van bredere genotypische screening in 
het geval van phenotypische variatie in reactie op dezelfde mutatie. 
Waar de KLF1 niveaus in Hoofdstuk vier variëren als gevolg van een afwijking in 
individuele individuele genetische achtergrond, kan het ook voorkomen dat een 
transcriptie factor als gevolg van een genetisch afwijking verminderd kan binden aan 
bepaalde DNA sequenties. Dit is het geval in het muis-model met de neonatale anemie 
mutatie, ook wel nan-model genoemd, die wij in meer detail hebben onderzocht in 
Hoofdstuk vijf. 
In dit model resulteert een genetische mutatie in een aminozuur substitutie op een 
centrale plek in het DNA-bindingsdomein van KLF1. In mensen resulteert een mutatie 
op de overeenkomstige locatie in congenitaal dysterythropoietic anemia type IV. Dit is 
een dodelijke vorm van anemie die als onderdeel van het ziektebeeld naast de expressie 
van volwassen globine ketens ook een hoge expressie van foetaal hemoglobine kent. 
Het overblijven van foetaal hemoglobine in volwassen cellen, vonden wij terug in 
het nan-model. Het lijkt daarmee dat hoewel hemoglobin switching tussen mensen en 
muizen op bepaalde punten verschilt, anemie en het overblijven van foetaal hemoglobine 
gedeelde fenotypische eigenschappen zijn die samenvallen met veranderingen in DNA 
binding. Tegelijkertijd zijn er net als in Hoofdstuk vier verschillen in de phenotypes 
uiting van overeenkomstige mutaties aan KLF1. Nader onderzoek zal moeten uitwijzen 
of dit komt door intrinsieke verschillen tussen muis en mensen of door andere DNA 
bindingseigenschappen van de twee KLF1 varianten. 
Tot slot
In de algemene discussie (Hoofdstuk 6) bespreek ik de belangrijkste bevindingen 
uit de thesis in een bredere context. Ik ga in op de rol van stress erytropoëse in 
gekweekte cellen, de invulling van de omgevingssignalen en hun invloed op foetaal 
hemoglobine expressie. 
